

WSES guidelines for management of Clostridium difficile infection in surgical patients

Sartelli, Massimo; Malangoni, Mark A.; Abu-Zidan, Fikri M.; Griffiths, Ewen A.; Di Bella, Stefano; McFarland, Lynne V.; Eltringham, Ian; Shelat, Vishal G.; Velmahos, George C.; Kelly, Ciarán P.; ...

Source / Izvornik: **World Journal of Emergency Surgery, 2015, 10, 38 - 38**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/doi: 10.1186/s13017-015-0033-6>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:105:407529>

Rights / Prava: [In copyright](#) / [Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2024-07-28**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine
Digital Repository](#)



REVIEW

Open Access



WSES guidelines for management of *Clostridium difficile* infection in surgical patients

Massimo Sartelli^{1*}, Mark A. Malangoni², Fikri M. Abu-Zidan³, Ewen A. Griffiths⁴, Stefano Di Bella⁵, Lynne V. McFarland⁶, Ian Eltringham⁷, Vishal G. Shelat⁸, George C. Velmahos⁹, Ciarán P. Kelly¹⁰, Sahil Khanna¹¹, Zaid M. Abdelsattar¹², Layan Alrahmani¹³, Luca Ansaloni¹⁴, Goran Augustin¹⁵, Miklosh Bala¹⁶, Frédéric Barbut¹⁷, Offir Ben-Ishay¹⁸, Aneel Bhangu¹⁹, Walter L. Biffi²⁰, Stephen M. Brecher²¹, Adrián Camacho-Ortiz²², Miguel A. Caínzos²³, Laura A. Canterbury²⁴, Fausto Catena²⁵, Shirley Chan²⁶, Jill R. Cherry-Bukowiec²⁷, Jesse Clanton²⁸, Federico Coccolini¹⁴, Maria Elena Cocuz²⁹, Raul Coimbra³⁰, Charles H. Cook³¹, Yunfeng Cui³², Jacek Czepiel³³, Koray Das³⁴, Zaza Demetrashvili³⁵, Isidoro Di Carlo³⁶, Salomone Di Saverio³⁷, Irina Magdalena Dumitru³⁸, Catherine Eckert³⁹, Christian Eckmann⁴⁰, Edward H. Eiland⁴¹, Mushira Abdulaziz Enani⁴², Mario Faro⁴³, Paula Ferrada⁴⁴, Joseph Derek Forrester⁴⁵, Gustavo P. Fraga⁴⁶, Jean Louis Frossard⁴⁷, Rita Galeiras⁴⁸, Wagih Ghnam⁴⁹, Carlos Augusto Gomes⁵⁰, Venkata Gorrepati⁵¹, Mohamed Hassan Ahmed⁵², Torsten Herzog⁵³, Felicia Humphrey⁵⁴, Jae Il Kim⁵⁵, Arda Isik⁵⁶, Rao Ivatury⁴⁴, Yeong Yeh Lee⁵⁷, Paul Juang⁵⁸, Luis Furuya-Kanamori⁵⁹, Aleksandar Karamarkovic⁶⁰, Peter K Kim⁶¹, Yoram Kluger¹⁸, Wen Chien Ko⁶², Francis D. LaBarbera⁵¹, Jae Gil Lee⁶³, Ari Leppaniemi⁶⁴, Varut Lohsiriwat⁶⁵, Sanjay Marwah⁶⁶, John E. Mazuski⁶⁷, Gokhan Metan⁶⁸, Ernest E. Moore²⁰, Frederick Alan Moore⁶⁹, Carl Erik Nord⁷⁰, Carlos A. Ordoñez⁷¹, Gerson Alves Pereira Júnior⁷², Nicola Petrosillo⁵, Francisco Portela⁷³, Basant K. Puri⁷⁴, Arnab Ray⁵⁴, Mansoor Raza⁷⁵, Miran Rems⁷⁶, Boris E. Sakakushev⁷⁷, Gabriele Sganga⁷⁸, Patrizia Spigaglia⁷⁹, David B. Stewart⁸⁰, Pierre Tattevin⁸¹, Jean Francois Timsit⁸², Kathleen B. To²⁷, Cristian Tranà⁸³, Waldemar Uhl⁵³, Libor Urbánek⁸⁴, Harry van Goor⁸⁵, Angela Vassallo⁸⁶, Jean Ralph Zahar⁸⁷, Emanuele Caproli⁸⁸ and Pierluigi Viale⁸⁹

Abstract

In the last two decades there have been dramatic changes in the epidemiology of *Clostridium difficile* infection (CDI), with increases in incidence and severity of disease in many countries worldwide. The incidence of CDI has also increased in surgical patients. Optimization of management of *C. difficile*, has therefore become increasingly urgent. An international multidisciplinary panel of experts prepared evidenced-based World Society of Emergency Surgery (WSES) guidelines for management of CDI in surgical patients.

Executive summary

In the last two decades, the dramatic increase in incidence and severity of *Clostridium difficile* infection (CDI) in many countries worldwide [1], has made CDI a global public health challenge [2–5]. Recently two comprehensive sets of guidelines for management of CDI were published [6, 7] that do not address issues specifically with regard to surgeons. CDI in surgical patients is

of particular interest. Surgery, especially gastrointestinal surgery, may predispose patients to the development of CDI. Surgery is also a treatment option in severe cases of CDI [8–11]. Optimization of the perioperative CDI patient management is therefore necessary for reduction in health care costs, as well as patient morbidity and mortality. To provide empirical guidelines for the surgeon called upon to assist in the care of the CDI patient, an international multidisciplinary panel of experts worldwide have prepared these evidenced-based guidelines for the management of *C. difficile* infection. In constituting the expert panel, the board of World Society of Emergency Surgery

* Correspondence: m.sartelli@virgilio.it

¹Department of Surgery, Macerata Hospital, Via Santa Lucia 2, 62019 Macerata, Italy

Full list of author information is available at the end of the article

(WSES) involves many of the world's leading surgical experts in management of CDI. This expert panel includes professionals who treat CDI patients on a daily basis as well as those with research interests in the condition. These guidelines outline clinical recommendations based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) hierarchy criteria summarized in Table 1 [12, 13].

Recommendations

Diagnosis

1) Stool testing should only be performed on diarrhea stools from at-risk patients with clinically significant diarrhea (Recommendation 1 C).

2) For patients with ileus who may be unable to produce stool specimens, polymerase chain reaction testing of perirectal swabs may be an accurate and efficient method to detect toxigenic *C. difficile* in patients with symptoms of CDI (Recommendation 2B).

3) Nucleic acid amplification tests (NAAT) such as polymerase chain reaction (PCR) for *C. difficile* toxin genes appear to be sensitive and specific and may be used as a standard diagnostic test for CDI. NAAT as single-step

algorithm can increase detection of asymptomatic colonization therefore it should only be performed in patients with clinical suspicion for CDI (Recommendation 1 B).

4) Glutamate dehydrogenase (GDH) screening tests for *C. difficile* are sensitive but do not differentiate between toxigenic and non-toxigenic strains. They may be used in association with toxin A and B EIA testing. Algorithms involving screening with an EIA for GDH followed by a toxin assay may be used (Recommendation 1 B).

5) Enzyme immunoassay (EIA) for toxin A/B is fast and inexpensive and has high specificity but it is not recommended alone due to its relatively low sensitivity. (Recommendation 1 B).

6) *Clostridium difficile* culture is relatively slow but sensitive. It is rarely performed today as a routine diagnostic test. *C. difficile* culture is recommended for subsequent epidemiological typing and characterization of strains (Recommendation 1 C).

7) Repeat testing within 7 days should not be performed on patients who previously tested negative unless the clinical picture has changed significantly (Recommendation 1 C).

Table 1 Grading of recommendations from Guyatt and colleagues [12, 13]

Grade of recommendation	Clarity of risk/benefit	Quality of supporting evidence	Implications
1A			
Strong recommendation, high-quality evidence	Benefits clearly outweigh risk and burdens, or vice versa	RCTs without important limitations or overwhelming evidence from observational studies	Strong recommendation, applies to most patients in most circumstances without reservation
1B			
Strong recommendation, moderate-quality evidence	Benefits clearly outweigh risk and burdens, or vice versa	RCTs with important limitations (inconsistent results, methodological flaws, indirect analyses or imprecise conclusions) or exceptionally strong evidence from observational studies	Strong recommendation, applies to most patients in most circumstances without reservation
1C			
Strong recommendation, low-quality or very low-quality evidence	Benefits clearly outweigh risk and burdens, or vice versa	Observational studies or case series	Strong recommendation but subject to change when higher quality evidence becomes available
2A			
Weak recommendation, high-quality evidence	Benefits closely balanced with risks and burden	RCTs without important limitations or overwhelming evidence from observational studies	Weak recommendation, best action may differ depending on the patient, treatment circumstances, or social values
2B			
Weak recommendation, moderate-quality evidence	Benefits closely balanced with risks and burden	RCTs with important limitations (inconsistent results, methodological flaws, indirect or imprecise) or exceptionally strong evidence from observational studies	Weak recommendation, best action may differ depending on the patient, treatment circumstances, or social values
2C			
Weak recommendation, Low-quality or very low-quality evidence	Uncertainty in the estimates of benefits, risks, and burden; benefits, risk, and burden may be closely balanced	Observational studies or case series	Very weak recommendation; alternative treatments may be equally reasonable and merit consideration

8) Immunocompromised patients (including patients in chemotherapy, chronic corticosteroid therapy or immunosuppressive agents, and post-transplant patients) should be always tested for CDI if they have a diarrheal illness (Recommendation 1 C).

9) CT imaging is suggested for suspected severe-complicated *C. difficile* colitis, however its sensitivity is not satisfactory for screening purposes (Recommendation 2 B).

10) Ultrasound may be useful in critically ill patients suspected to have pseudomembranous colitis who cannot be transported for CT scan (Recommendation 2 C).

11) Flexible sigmoidoscopy may be helpful for the diagnosis of *C. difficile* colitis (CDC) when there is a high level of clinical suspicion for *C. difficile* despite repeated negative laboratory assays (Recommendation 2 B).

Antimicrobial therapy

12) Unnecessary antimicrobial agent(s) and proton pump inhibitors should be discontinued if CDI is suspected (Recommendation 1 C).

13) Empirical therapy for CDI should be avoided unless there is a strong suspicion for CDI. If a patient has a strong suspicion for CDI, empirical therapy for CDI should be considered while awaiting test results (Recommendation 1 B).

14) Metronidazole is recommended for the treatment of mild-moderate disease (Recommendation 1 A).

15) Oral vancomycin is recommended for treatment of patients with severe disease, or for patients with mild-moderate disease who do not respond to metronidazole. (Recommendation 1 A).

16) In patients in whom oral antibiotics cannot reach the colon, vancomycin may be administered by enema and metronidazole can be given intravenously (Recommendation 1 B).

17) Fidaxomicin may be used to treat CDI, especially in the patients at higher risk for recurrence (e.g. elderly patients with severe underlying disease or those requiring receiving concomitant antibiotics) (Recommendation 1 A).

Surgical management

18) Patients with severe CDI who progress to systemic toxicity should undergo early surgical consultation and evaluated for potential surgical intervention (Recommendation 1 C).

19) Resection of the entire colon should be considered to treat patients with fulminant colitis (FC) (Recommendation 1 B).

20) Diverting loop ileostomy with colonic lavage may be a useful alternative to resection of entire colon (Recommendation 2 C).

21) Patients with FC should be treated with high dose oral or by enema vancomycin (500 mg, 6 hourly) in

combination with intravenous metronidazole (500 mg, 8 hourly). (Recommendation 1 C).

Supportive care

22) Supportive measures, including intravenous fluid resuscitation and electrolyte replacement, should be provided to all patients with severe *C. difficile* infection (Recommendation 1 C).

23) Early detection of shock and aggressive management of underlying organ dysfunction are essential for optimum outcomes in patients with fulminant colitis (Recommendation 1 C).

Recurrent *C. difficile* infection (RCDI)

24) Agents that may be used to treat the first recurrence of CDI include metronidazole, for non-severe RCDI, and vancomycin for severe RCDI. (Recommendation 1 B).

25) Fidaxomicin may be used as an alternative agent (Recommendation 1 B).

26) In subsequent recurrence of CDI (2nd or later) oral vancomycin or fidaxomicin is recommended (Recommendation 1 B).

Probiotics

27) Probiotics may be considered as an adjunctive treatment to antibiotics for immunocompetent patients with RCDI (Recommendation 2 B).

Faecal microbiota transplantation

28) Intestinal or faecal microbiota transplantation (IMT or FMT) may be an effective option for the treatment of RCDI (Recommendation 1 B).

29) FMT may be effective in immunocompromised patients and patients who have had solid organ transplants (Recommendation 2 B).

Intravenous immunoglobulin (IVIG)

30) IVIG should only be used as adjunct therapy in patients with multiple recurrent or fulminant CDI until results from large, randomized controlled trials are available (Recurrence 2 C).

Monoclonal antibodies

31) Infusion with monoclonal antibodies may be of use to prevent recurrences of CDI, particularly in patients with CDI due to the 027 epidemic strain (Recommendation 2 C).

Enteral nutrition in CDI

32) Tube feeding patients should be clinically assessed due to their risk for developing CDI (Recommendation 2 C).

Anti-motility agents

33) The use of anti-peristaltic agents for the treatment of CDI should be discouraged. If anti-peristaltic, if used in isolation agents, are used to control persistent symptoms in patients with CDI they must always be accompanied by medical therapy (Recommendation 2 C).

Prevention

34) Proper antimicrobial stewardship in selecting an appropriate antibiotic and optimizing its dose and duration to cure an infection may prevent the emergence of *C. difficile* (Recommendation 1 B).

35) Patients with suspected or proven CDI should be placed in contact (enteric) precautions (Recommendation 1 B).

36) Hand hygiene with soap and water is a cornerstone of the prevention of *C. difficile*. Hand hygiene, contact precautions and good cleaning and disinfection of the environment and patient care equipment, should be used by all health-care workers contacting any patient with known or suspected CDI (Recommendation 1 B).

Introduction

C. difficile is an anaerobic, spore forming Gram-positive bacillus, which may form part of the normal intestinal microbiota in healthy newborns but which is rarely present in the gut of healthy adults [14–16]. The organism is spread via the oral-fecal route and in hospitalized patients may be acquired through the ingestion of spores or vegetative bacteria spread to patients by healthcare personnel's hands or from the environment [17, 18]. It is the most common cause of diarrhea in hospitalized patients.

Pathogenesis

Clostridium difficile spores survive the acidic environment of the stomach and germinate in the intestine [19]. They act as an environmental reservoir for *C. difficile* and can facilitate spread among patients, as well as contributing to the high recurrence rates observed in CDI. The primary toxins produced by this bacterium are toxins A and B [20]. Some strains of *C. difficile* also produce binary toxin. Toxins A and B act as glucosyltransferases, promoting the activation of Rho GTPases leading to disorganization of the cytoskeleton of the colonocyte, and eventual cell death [21]. Since CDI is a toxin mediated infection, non toxigenic *C. difficile* strains are non-pathogenic. Over the years the respective roles and importance toxins A and B has been debated. Toxin A was thought to be the major virulence factor for many years, [22–24]. It is now established that both toxins A and B are important for inducing colonocyte death and colitis. In addition to toxins A and B, some strains produce a third toxin known as binary toxin [25–29]. Binary toxin has an ADP-ribosyltransferase function, which also leads to actin

depolymerization [30, 31]. It has been demonstrated in *C. difficile* strains associated with nosocomial outbreaks of CDI with increased clinical severity [32, 33].

Typing is useful to differentiate *C. difficile* strains and to obtain epidemiological information. Different typing methods for *C. difficile* are actually available: restriction endonuclease analysis (REA), pulsed-field gel electrophoresis (PFGE), multilocus sequence typing (MLST), repetitive-element PCR typing, toxinotyping, multilocus variable-number tandem-repeat analysis (MLVA) and PCR- ribotyping [34].

C. difficile strains with increased virulence traits (hyper virulent), have been described in the last 10 years. In particular, PCR-ribotype 027, also known as North American pulsed-field gel electrophoresis type 1 (NAP1) or restriction endonuclease analysis group BI, has been associated with increased disease severity, recurrence and significant mortality [35].

Asymptomatic colonization may occur in 6 to 50 % of long-term care facility residents depending on whether CDI is endemic [36, 37]. In a 15-month prospective study of 4143 patients performed in six Canadian hospitals in Quebec and Ontario [38], 184 (4.4 %) had asymptomatic colonization at the time of unit admission, and 123 (3.0 %) had health care-associated *C. difficile* colonization.

Risk factors

Risk factors for CDI may be divided into three general categories: host factors (immune status, co-morbidities), exposure to CD spores (hospitalizations, community sources, long-term care facilities) and factors that disrupt normal colonic microbiome (antibiotics, other medications, surgery) [39].

Host factors

Risk factors identified to date include, age more than 65 years, comorbidity or underlying conditions, inflammatory bowel diseases, immunodeficiency (including human immunodeficiency virus infection, hematologic malignancies and chemotherapy), malnutrition, and low serum albumin level [3, 40]. Diabetes mellitus is increasingly recognized as a risk factor for hospital and community-acquired CDI [41]. More recently, gene polymorphisms (e.g. IL-8) may be associated with increased risk for CDI but further studies are needed [42].

The effect of prior appendectomy on the development of *C. difficile* colitis has been debated in literature [43].

A recent review by Seretis et al. [44] of five studies conducted retrospectively was published in 2014. Although the results were conflicting regarding the impact of prior appendectomy on the occurrence or relapse of CDI, it appeared that an *in situ* appendix did not impact on the development of CDI.

In the retrospective analysis by Clanton et al. [45] on 55 patients who underwent colectomy for CDI between 2001 and 2011, a prior appendectomy was noted in 24 of 55 specimens (44, 99 % CI: 0.280–0.606). This was compared to an observed lifetime rate of appendectomy of 17.6 %. The rate of appendectomy in the cohort of patients who later underwent colectomy for CDI was significantly higher than would be expected in the general population (44 % vs 18 %, $P < 0.01$).

In a second retrospective study [46], of 388 patients with an intact appendix, 20 (5.2 %) developed fulminant infection and required colectomy, whereas of the 119 patients with a previous appendectomy, 13 (10.9 %) required colectomy. An increased severity of disease, indicated by increased rate of colectomy, occurred for the group with a history of appendectomy ($P = 0.03$).

A sub-group analysis of a large population based study published in 2013 [47] showed that appendectomy was not associated with adverse outcomes in CDI. Patients with appendectomy before CDI had no differences in risk factors, treatment, or outcomes including treatment failure, development of severe or severe-complicated CDI, and recurrence rates as compared with patients without appendectomy.

Larger prospective studies are needed to assess the impact of prior appendectomy on development and severity of CDI.

Exposure to *Clostridium difficile* spores

Factors that increase risk of exposure to *C. difficile* spores, such as increased duration of hospital stay may increase the risk of CDI. A length of stay > 2 weeks has been shown to be a risk factor for CDI [48]. Hospitals with well implemented infection prevention and control measures may reduce the risk of patients of developing CDI [49].

Normal flora disruption

The indigenous gut microbiota is the complex community of microorganisms that populates the gastrointestinal tract. This micro-ecosystem plays a crucial role in protecting the intestines by providing resistance to colonization and infection by pathogenic organisms [50]. Gut microbiota also has immeasurable effects on homeostasis in the host [51]. Under normal conditions, the human gut microbiota may impede pathogen colonisation through general mechanisms such as direct inhibition through bacteriocins, nutrient depletion (consuming growth-limiting nutrients) or stimulation of host immune defences [38] though the exact mechanism by which the microbiota protects against CDI is unknown [52]. Disruption of the normal balance of colonic microbiota as a consequence of antibiotic use or other stressors, is, however, likely to be important [53].

Antibiotic exposure

It is presumed that disruption of the normal gut flora provides a perfect setting for *C. difficile* to proliferate and produce toxin.

The risk of CDI is increased up to 6-fold during and in the subsequent month after antibiotic therapy [54]. Although nearly all antibiotics have been associated with CDI, clindamycin, third-generation cephalosporins, penicillins and fluoroquinolones have traditionally been considered to pose the greatest risk [55–61]. An association between CDI and antimicrobial treatment > 10 days has also been demonstrated [62, 63]. Antibiotics which have been less commonly associated with CDI include macrolides, sulfonamides and tetracyclines [64]. Even very limited exposure, such as single-dose surgical antibiotic prophylaxis may increase patients risk for both *C. difficile* colonization [65, 66] or infection.

Other medications

Exposure to gastric acid-suppressive medications, such as histamine-2 blockers and proton pump inhibitors (PPIs) may be a potential risk factor for development of CDI. Recent studies have suggested the association between use of stomach acid-suppressive medications, primarily PPIs, and CDI [67, 68]. In 2012 a systematic review of [69] 42 observational studies (30 case-control, 12 cohort) totalling 313,000 participants were evaluated for incident and recurrent CDI in PPI users. Despite the substantial statistical and clinical heterogeneity, the findings indicated a probable association between PPI use and incident and recurrent CDI. This risk was further increased by concomitant use of antibiotics and PPI. Other studies suggested that this association may be the result of confounding with the underlying severity of illness and duration of hospital stay [70]. Given that acid suppression drugs, especially PPIs, may be over-prescribed in surgical settings consideration should be given to stopping PPIs in patients at high risk of CDI.

Surgery

Recent reports have linked the development of CDI in surgical patients with widespread use of broad-spectrum antibiotics, increasing numbers of elderly and immunocompromised patients undergoing surgical interventions and the emergence of more virulent strains of *C. difficile* [8, 71, 72].

Abdelsattar et al. [11] prospectively identified patients with laboratory-confirmed postoperative CDI after different general, vascular, or gynaecological surgeries at 52 academic and community hospitals in the state of Michigan, USA between July 2012 and September 2013. The highest rates of CDI occurred after lower-extremity amputation (2.6 %), followed by bowel resection or repair (0.9 %) and gastric or esophageal operations (0.7 %). Gynaecological

and endocrine operations had the lowest rates (0.1 and 0 %, respectively). Using multivariable analyses, older age, chronic immunosuppression, hypoalbuminemia (≤ 3.5 g/dL) and preoperative sepsis were associated with CDI. Use of prophylactic antibiotics was not independently associated with CDI, neither was sex, body mass index (BMI), surgical priority, weight loss, or comorbid conditions.

Zerey et al. [8] performed a five-year retrospective analysis of the Agency for Healthcare Research and Quality's National Inpatient Sample Database representing a stratified 20 % sample of hospitals in the United States, from 1999 to 2003. Patients undergoing an emergency operation were at higher risk of CDI than those having operations performed electively. Colectomy, small-bowel resection, and gastric resection were associated with the highest risk of CDI. Patients undergoing cholecystectomy and appendectomy had the lowest risk.

In 2010, Rodriguez et al. [73] published a retrospective analysis of all general surgery inpatients admitted to a large tertiary referral general surgical unit in the United Kingdom, between March 2005 and May 2007. Multivariate analysis identified malignancy, gastrointestinal disease, anemia, respiratory disease, circulatory disease, diabetes mellitus, those undergoing gastrointestinal surgery and increasing age to be independently associated with *C. difficile*.

To assess risk factors associated with CDI on a surgical ward, in 2012 Kim et al. conducted a retrospective chart review of all patients admitted between January 2010 and July 2011 [74]. The rate of CDI occurrence was 0.4 % (19/4,720 patients). Multivariate analysis showed that colectomy and hospital stays longer than 10 days were the highest risk factors for CDI occurrence in the surgical ward.

Using the Japanese Diagnosis Procedure Combination inpatient database, Yasunaga et al. [75] analyzed factors affecting the occurrence of CDI and the outcomes of CDI following digestive tract surgery. Of 143,652 patients undergoing digestive tract surgery, CDI was identified in 409 (0.28 %) patients. High mortality, long hospital stay and high costs were associated with postsurgical CDI.

Colo-rectal surgery is known as risk factor for CDI in surgical patients [76, 77]. Recently Damle et al. [78] published a retrospective analysis of patients who developed CDI following colorectal resection. Utilizing the U.S. University Health System Consortium database the authors identified adult patients undergoing colorectal surgery between 2008 and 2012. A total of 84,648 patients met study inclusion criteria. CDI occurred in 1,266 (1.5 %) patients during the study period. The strongest predictors of CDI were emergency procedure, inflammatory bowel disease, and severity of illness score. CDI was associated with a higher rate of complications, intensive

care unit (ICU) admission, longer preoperative inpatient stay, 30-day readmission rate, and death within 30 days compared to non-CDI patients.

In 2008 Lumpkins et al. [79] published a retrospective observational study about the incidence of CDI in the critically injured trauma population. Five hundred eighty-one consecutive critically injured trauma patients were followed prospectively for development of CDI, diagnosed by toxin assay. Among 581 patients 19 cases of CDI were diagnosed (3.3 %). Intensive care unit length of stay, ventilator days, and hospital length of stay were significantly higher in the CDI patients. The diagnosis was made at mean of 17 days after admission; however, in four patients (21 %), the infections were diagnosed within six days of admission. Fourteen patients (74 %) had received therapeutic antibiotics for confirmed or suspected infection prior to the appearance of colitis; four patients (21 %) received only intraoperative prophylaxis, and one patient had no antibiotic exposure.

Recently Egorova et al. [80] reviewed the trend, hospital variability in CDI rates, in vascular surgery in USA. The rates of CDI after major vascular procedures including aortic abdominal aneurysm (AAA) repair, carotid endarterectomy or stenting, lower extremity revascularization (LER), and LE amputation were identified using Nationwide Inpatient Sample database for 2000–2011. During the study period the rates of CDI after vascular procedures had increased by 74 % from 0.6 in 2000 to 1.05 % in 2011. In 2011, the highest rates were after ruptured AAA repair (3.3 %), followed by lower extremity amputations (2.3 %), and elective open AAA (1.3 %).

Inflammatory bowel disease (IBD)

Patients with inflammatory bowel disease (IBD) may have increased risk of developing CDI, along with worse outcomes, higher rates of colectomy and higher rates of recurrence [81–84]. Patients with IBD also appear to have higher rates of asymptomatic carriage of *C. difficile* [85]. They receive various types of immunosuppressive drugs including steroids that has been found to increase the risk of CDI [86, 87].

The clinical presentation of an IBD exacerbation and CDI often is indistinguishable and requires a high index of suspicion for adequate treatment [6]. As the symptoms of CDI and an exacerbation of IBD (diarrhea, abdominal pain, fever and leukocytosis) overlap, the diagnosis of CDI may be delayed if it is not tested for [88]. In addition, in IBD patients with ileostomies, the development of acute enteritis as manifested by an increase in ileostomy output, nausea, fever and leukocytosis may also indicate CDI. The same is true for pouchitis, which presents as an increase in the number of stools per day [89]. In one study 10.7 % of patients with ileal pouch anal anastomosis, presenting with pouchitis, were found to have CDI [90].

In patients with IBD and severe colitis, empirical therapy directed against both CDI and treatment of an IBD flare should be started simultaneously while awaiting results of *C. difficile* testing [6].

Due to high rates of asymptomatic colonization of *C. difficile* in patients with IBD, only patients with increased diarrhea or new symptoms attributable to CDI should be tested for *C. difficile* toxin. Typical findings of CDI on colonoscopy are often absent in patients with IBD (0–13 % of cases) [91] which may be attributed to a weakened inflammatory response. There is no evidence from prospective studies to suggest that one antibiotic regimen is better than another for the treatment of CDI in IBD patients. Considering the worse outcomes seen in patients with IBD and CDI, some institutions use vancomycin as first line therapy. In a survey of North American gastroenterologists, there was no agreement on combination of antibiotics and immunomodulators in patients with an IBD flare and CDI [92]. The American College of Gastroenterology recommended with low quality supporting evidence, that ongoing immunosuppression can be maintained in patients with CDI but escalation of immunosuppression should be avoided.

Physicians should remain alert to the possibility of CDI in a patient with an IBD exacerbation to ensure rapid diagnosis and treatment. Early surgical consultation is also key for improving outcomes of patients with severe disease. Colectomy with preservation of the rectum may need to be considered for severely ill IBD patients with CDI.

Immunocompromise patients

It is well known that the rate of CDI in the post-transplant setting is higher [93]. It has also been reported that cancer patients have a higher risk compared with non-cancer patients [94] due to chemotherapy causing the immunosuppression. Recently two retrospective studies were published on CDI in cancer patients [95, 96].

In the first a total of 225 patients were included, and 39 of them (17.3 %) were diagnosed with CDI. Type of tumor significantly differed between CDI patients, thus relative risk in each type of cancer was calculated after adjusting for age, antibiotic exposure, corticosteroid, and proton-pump inhibitor use. Patients with gastrointestinal tumors were less prone to CDI. Conversely, breast cancer patients have a greater predisposition to CDI. Antibiotic treatment was found to be associated with an increasing risk for CDI in breast cancer patients [95].

In the second study of 277 cancer patients with diarrhea 41 (14.8 %) were *C. difficile* toxin-positive. Multivariate analysis showed that chemotherapy (OR, 8.308; 95 % CI, 1.997–34.572; $P = 0.004$) and a positive result of fecal occult blood test (OR, 8.475; 95 % CI, 1.463–

49.109; $P = 0.017$) were independent risk factors for acquisition of CDI among cancer patients [96].

Patients with HIV/AIDS are at a high risk of being infected with *C. difficile* too. This relationship is stronger in those with low absolute CD4 T cell counts or who meet clinical criteria for an AIDS diagnosis [97].

The increased risk may be partially attributed to frequent hospitalization, exposure to antibiotics and antibiotic prophylaxis for opportunistic infections, but HIV related alterations in fecal microbiota, gut mucosal integrity, and humoral and cell mediated immunity may be also likely to play a role [98].

Community-acquired *C. difficile* infection (CA-CDI)

Community-acquired CDI (CA-CDI) has been demonstrated in populations previously thought to be at low-risk, including younger patients not previously exposed to antibiotics [99]. Suggested risk factors include increasing outpatient antibiotic prescriptions, greater use of acid-suppression medications, an increase in the proportion of asymptomatic carriers in the community and novel risk factors like food and water contamination [100]. A sub-group analysis of a population-based epidemiological study of CDI in Olmsted County, Minnesota from 1991–2005 was published in 2012 [101]. Of 157 CA-CDI cases, the median age was 50 years and 75.3 % were female. Among CA-CDI cases, 40 % required hospitalization, 20 % had severe and 4.4 % had severe-complicated infection, 20 % had treatment failure and 28 % had recurrent CDI.

Recently a systematic review and meta-analysis investigated the association between commonly prescribed medications and comorbidities with CA-CDI [41]. Twelve publications ($n = 56,776$ patients) met inclusion criteria. Antimicrobial (odds ratio, 6.18; 95 % CI 3.80–10.04) and corticosteroid (1.81; 1.15–2.84) exposure were associated with increased risk of CA-CDI. Among the comorbidities, inflammatory bowel disease (odds ratio, 3.72; 95 % CI, 1.52–9.12), renal failure (2.64; 1.23–5.68), hematologic cancer (1.75; 1.02–5.68), and diabetes mellitus (1.15; 1.05–1.27) were associated with CA-CDI. By location, antimicrobial exposure was associated with a higher risk of CA-CDI in the United States, whereas proton-pump inhibitor exposure was associated with a higher risk in Europe. By life stages, the risk of CA-CDI associated with antimicrobial exposure greatly increased in adults older than 65 years.

Risk factors for recurrent CDI

In a meta-analysis by Garey et al. [102] found that continued use of non-*C. difficile* antibiotics after diagnosis of CDI (OR: 4.23; 95 % CI: 2.10–8.55; $P < 0.001$), concomitant receipt of antacid medications (OR: 2.15; 95 % CI: 1.13–4.08; $P = 0.019$), and older age (OR: 1.62; 95 % CI: 1.11–2.36; $P = 0.0012$) were significantly associated

with an increased risk of recurrent CDI. Other factors identified in individual studies include age, hospital exposure, comorbid conditions, severe underlying illness, poor quality of life scores, initial disease severity and previous recurrent CDI [103, 104].

A recent systematic review and meta-analysis [105] was published to evaluate current evidence on the risk factors for recurrent CDI. A total of 33 studies ($n = 18,530$) met the inclusion criteria. The most frequent independent risk factors associated with recurrent CDI were age ≥ 65 years (risk ratio [RR], 1.63; 95 % confidence interval [CI], 1.24–2.14; $P = .0005$), additional antibiotics during follow-up (RR, 1.76; 95 % CI, 1.52–2.05; $P < .001$), use of proton-pump inhibitors (PPIs) (RR, 1.58; 95 % CI, 1.13–2.21; $P = .008$), and renal insufficiency (RR, 1.59; 95 % CI, 1.14–2.23; $P = .007$). The risk was also greater in patients previously on fluoroquinolones (RR, 1.42; 95 % CI, 1.28–1.57; $P < .001$).

Clinical manifestations

The spectrum of symptomatic CDI ranges from mild diarrhea to severe disease or fulminant colitis and as many as 30 % of patients may develop recurrent CDI [106, 107].

Though diarrhea is the hallmark symptom of CDI it may not be present initially, possibly due to colonic dysmotility either from previous underlying conditions or possibly from the disease process itself [108].

This is especially important in surgical patients who may have a concomitant ileus. Therefore, in surgical patients it is important to have a high index of suspicion for the development of CDI.

Mild-moderate CDI

Diarrhea may be accompanied by mild abdominal pain and cramps and if prolonged may result in altered electrolyte balance and dehydration. When this occurs in patients with severe comorbidity, particularly after surgery, non-severe CDI may increase morbidity significantly [109].

Severe CDI

Severe CDI is associated with increased abdominal cramping and pain and constitutional features such as fever, leukocytosis, and hypoalbuminemia. The absence of diarrhoea in these patients may signal a progression to fulminant infection [110]. Though a wide variety of severity predictors for severe CDI has been described [111–115] international consensus for the definition of severe CDI is lacking [6, 7, 116].

One systematic review identifying risk factors for adverse outcomes of CDI was published by Abou Chakra et al. in 2012 [114]. Except for leukocytosis, albumin and age, there was much heterogeneity in the data and most studies were limited by small sample sizes.

To investigate the prognostic value of fever, leukocytosis, and renal failure, Bauer et al. [113] in 2012 analyzed the database of two randomized controlled trials, which contained information for 1105 patients with CDI. They found that both leukocytosis and renal failure were useful predictors of a complicated course of CDI. Miller et al. [115] in 2013 subsequently published an analysis of the same two clinical therapeutic trials to validate a categorization system to stratify CDI patients into severe or mild-moderate groups. A combination of five simple and commonly available clinical and laboratory variables (ATLAS) measured at the time of CDI diagnosis were able to accurately predict treatment response to CDI therapy. The ATLAS criteria included: age, treatment with systemic antibiotics, leucocyte count, albumin and serum creatinine [115].

Any of the following may be predictors of severe CDI:

- WBC $>15 \times 10^9/L$
- Acutely rising serum creatinine
- Temperature $>38.5^\circ C$
- Albumin $<2.5 \text{ mg/dL}$

The progression to fulminant *C. difficile* colitis is relatively infrequent [109] (1–3 % of all CDI) although mortality in this group of patients remains high due to the development of toxic megacolon with colonic perforation, peritonitis and septic shock and subsequent organ dysfunction. Systemic symptoms may result from toxin-induced inflammatory mediators released locally in the colon [117–119]. Studies have demonstrated a significant rise in the number of cases of fulminant colitis associated with multiple organ failure and increased mortality in recent years associated with the hypervirulent 027 strain of *C. difficile* [120, 121]. Early diagnosis and treatment is therefore important in reducing the mortality associated with fulminant colitis. Patients who present with organ failure including increased serum lactate or vasopressor requirements, should be assessed immediately with regard to early operative intervention [121].

Recurrent CDI (RCDI)

Recurrence of symptoms after initial therapy for *C. difficile*, develops in 10–30 % of cases, and this often presents a clinical challenge. Patients may have several episodes of recurrence that may occur over a period of years [122–127]. Recurrence and reinfection are therefore difficult to distinguish by symptoms alone, but may be distinguished if the strain of *C. difficile* is typed.

RCDI may be either a consequence of germinating resident spores remaining in the colon after antibiotic treatment has stopped, or re-infection from an environmental source.

Even though consensus regarding factors associated with CDI recurrence is not universal learning algorithms

have been developed to predict CDI recurrence with good sensitivity [128].

Ultimately distinction between recurrence and reinfection can only be achieved if the strain of *C. difficile* is 'typed' using molecular epidemiology [129].

Wider consequences of CDI

Patients who develop CDI have increased hospital length-of-stay, higher medical care costs, more hospital re-admissions, and higher mortality [130–132].

These consequences are also found for surgical patients with CDI.

In the Zerey et al. analysis [8] epidemiologic data suggested that the infection was most prevalent after emergency operations and among patients having intestinal tract resections. Infection with *C. difficile* was an independent predictor of increased length of stay, which increased by 16.0 days (95 % CI 15.6, 16.4 days; $p < 0.0001$) in the presence of infection. Total charges increased by \$77,483 (95 % CI \$75,174, \$79,793; $p < 0.0001$), and there was a 3.4-fold increase in the mortality rate (95 % CI 3.02, 3.77; $p < 0.0001$) compared with patients who did not acquire *C. difficile*.

In the Abdelsattar et al. study [11] three procedure groups had higher odds of postoperative CDI: lower-extremity amputations (adjusted odds ratio [aOR], 3.5; $P = .03$), gastric or esophageal operations (aOR, 2.1; $P = .04$), and bowel resection or repair (aOR, 2; $P = .04$). Postoperative CDI was independently associated with increased length of stay (mean, 13.7 days vs 4.5 days), emergency department presentations (18.9 vs 9.1 %) and readmissions (38.9 vs 7.2 %, all $P < .001$).

Data from Nationwide Inpatient Sample database in patients who underwent vascular surgery [79], showed that in 2011 patients who had experienced CDI had median length of stay 15 days (IQR 9, 25 days) compared with 8.3 days for matched patients without CDI, in-hospital mortality 9.1 % (compared to 5.0 %), and \$13,471 extra cost per hospitalization. The estimated cost associated with CDI in vascular surgery in the United States was about \$98 million in 2011. Data from the National Inpatient Sample examined just patients with lumbar surgery and found CDI increased length of stay by 8 days, hospital costs by 2-fold and increased inpatient mortality by 36-fold [133].

Higher mortality was also observed for liver transplant recipients (from 2000 to 2010) at Detroit hospital [134].

The ACS-NSQIP database from 2005 to 2010 was used by Lee et al. to study emergently performed open colectomies for a primary diagnosis of *C. difficile* colitis in US [135]. The overall mortality was 33 % (111/335). Age 80 years or older, preoperative dialysis dependence, chronic obstructive pulmonary disease), and wound class III were

associated to patients mortality. Thrombocytopenia (platelet count $< 150 \times 10^3/\text{mm}^3$), coagulopathy (International Normalized Ratio > 2.0), and renal insufficiency (blood urea nitrogen $> 40 \text{ mg/dL}$) were associated with a higher mortality as well.

Recently a study was performed to quantify additional hospital stay attributable to CDI in four European countries, by analyzing nationwide hospital-episode data [5]. Patients in England had the longest additional hospital stay attributable to CDI at 16.09 days, followed by Germany at 15.47 days, Spain at 13.56 days, and The Netherlands at 12.58 days, derived using regression analysis. Propensity score matching indicated a higher attributable length of stay of 32.42 days in England, 15.31 days in Spain, and 18.64 days in The Netherlands. Outputs from this study consistently demonstrate that in European countries, for patients whose hospitalization is complicated by CDI, the infection causes a statistically significant increase in hospital length of stay.

Recommendations for the management of CDI

Diagnosis

1) Stool testing should only be performed on diarrhea stools from at-risk patients with clinically significant diarrhea (Recommendation 1 C).

2) For patients with ileus who may be unable to produce stool specimens, polymerase chain reaction testing of perirectal swabs may be an accurate and efficient method to detect toxigenic *C. difficile* in patients with symptoms of CDI (Recommendation 2B).

Prompt and precise diagnosis is important for the effective management of CDI.

Early identification of CDI allows early treatment and can potentially improve outcomes. Rapid isolation of infected patients is important in controlling the transmission of *C. difficile* [136].

The diagnosis of CDI is based on the presence of a clinical picture compatible with CDI and microbiological evidence of free toxin and/or the demonstration of toxigenic *C. difficile* in a diarrhea stool sample [136]. Clinical features include: diarrhea (defined as by passage of 3 or more unformed stools in 24 h), abdominal pain and cramps, abdominal distension, ileus (signs of severely disturbed bowel function) and toxic megacolon.

Since *C. difficile* can colonize the intestinal tract of healthy individuals, diagnostic testing for CDI should be performed only on diarrhea stools from symptomatic patients. Testing of formed stool can result in false positive tests, which may result in unnecessary antibiotic therapy.

One limitation of the reliance on stool specimens are the patients with suspected severe CDI complicated by ileus as these patients may be unable to produce specimens for testing. For these patients testing of perirectal swabs may be an accurate and efficient method to detect

toxigenic *C. difficile*. In 2012 Kundrapu et al. [137] described the results of a prospective study of 139 patients being tested for *Clostridium difficile* infection by polymerase chain reaction. The sensitivity, specificity, positive predictive value, and negative predictive value of testing perirectal swabs were 95.7, 100, 100, and 99.1 %, respectively. The authors concluded that for selected patients, perirectal swabs provided an acceptable alternative to stool specimen analysis. Clinical context such as a history of recent antibiotic administration and/or residence in hospital are useful in selecting patients for testing. Other signs such as fever, abdominal pain, leukocytosis, in combination with other laboratory tests (e.g. creatinine and serum lactate) are useful for defining severity of infection.

3) Nucleic acid amplification tests (NAAT) such as polymerase chain reaction (PCR) for *C. difficile* toxin genes appear to be sensitive and specific and may be used as a standard diagnostic test for CDI. NAAT as single-step algorithm can increase detection of asymptomatic colonization therefore it should only be performed in patients with clinical suspicion for CDI (Recommendation 1 B).

4) Glutamate dehydrogenase (GDH) screening tests for *C. difficile* are sensitive but do not differentiate between toxigenic and non-toxigenic strains. They may be used in association with toxin A and B EIA testing. Algorithms involving screening with an EIA for GDH followed by a toxin assay may be used (Recommendation 1 B).

5) Enzyme immunoassay (EIA) for toxin A/B is fast and inexpensive and has high specificity but it is not recommended alone due to its relatively low sensitivity. (Recommendation 1 B).

6) *Clostridium difficile* culture is relatively slow but sensitive. It is rarely performed today as a routine diagnostic test. *C. difficile* culture is recommended for subsequent epidemiological typing and characterization of strains (Recommendation 1 C).

7) Repeat testing within 7 days should not be performed on patients who previously tested negative unless the clinical picture has changed significantly (Recommendation 1 C).

The best standard laboratory test for diagnosis of CDI has not been clearly established [138]. In the past, toxigenic culture (TC) was accepted by many microbiologists as the method of choice for diagnosis of CDI. The procedure includes stool culture for *C. difficile* on a selective differential medium (cycloserine, cefoxitin, fructose agar or CCFA) and an assay to test the colonies for the ability to produce toxins. Despite the fact that TC is considered a gold standard method, there are significant issues including slow turnaround time and its inability to detect the presence of toxins in stool. This may also

lead to false positive results given up to 7 % of asymptomatic hospitalized patients may be colonized with toxigenic *C. difficile* [139].

However, TC can still be used as a confirmatory test in symptomatic patients with toxin positive/GDH assay(s)-negative stool samples. *C. difficile* culture is also necessary for subsequent epidemiological typing and characterization of strains.

The EIA for toxin A/B has been adopted by most clinical laboratories because it is fast, convenient and inexpensive [140]. However, studies have shown that sensitivity can be low. Toxin A + B EIA tests have a described sensitivity of 32–98 % and a specificity of 84–100 % [141].

Glutamate dehydrogenase (GDH) is an enzyme produced by *C. difficile* in relatively large amounts compared with toxins A and B [142, 143]. A positive GDH assay only documents the presence of *C. difficile* but it does not discriminate between toxigenic and non-toxigenic strains (about 20 % of the *C. difficile* population). Therefore, a second test for toxin production is necessary for confirmation. GDH screening tests for *C. difficile* used in association to toxin A + B EIA testing gives an accurate test result quickly [140, 141] even if the sensitivity of such strategy is lower than nucleic acid amplification tests (NAATs).

NAATs such as PCR for CD toxin genes have a high sensitivity and specificity, but not all laboratories routinely perform this assay [143]. A current topic of debate is whether a stool sample that was positive by a molecular assay needs to be tested with a confirmatory toxin assay [144] given it can also identify toxigenic *C. difficile* in asymptomatic patients. This underscores the importance of only testing patients with symptoms. There is no evidence suggesting that surgical patients should be diagnosed any differently than general medical patients.

8) Immunocompromised patients (including patients in chemotherapy, chronic corticosteroid therapy, or immunosuppressive agents, and post-transplant patients) should be always tested for CDI if they have a diarrheal illness (Recommendation 1 C).

It has already been highlighted that immunocompromised patients including those on glucocorticoids, or chemotherapy and post-transplant patients are at increased risk for CDI.

9) CT imaging is suggested for suspected severe-complicated *C. difficile* colitis, however its sensitivity is not satisfactory for screening purposes (Recommendation 2 B).

CT has been studied as an imaging modality for diagnosing *C. difficile* colitis [145–148]. Typical CT findings of CDC include colonic wall thickening, dilation, pericolic stranding, “accordion sign” (high-attenuation oral contrast in the colonic lumen alternating with low-attenuation inflamed mucosa), “double-halo sign, target

sign" (intravenous contrast displaying varying degrees of attenuation caused by submucosal inflammation and hyperemia), and ascites [149]. However, the most common finding, colonic wall thickening is non-specific and can be found in other forms of colitis, although it may be more pronounced in that caused by *C. difficile*.

In the Kirkpatrick et al. study [150], CT diagnosis of CDC was made with a sensitivity of 52 %, a specificity of 93 %, and positive and negative predictive values 88 %, and 67 % respectively. Sensitivity would have been increased to 70 % with no change in specificity if a colon wall thickness of greater than 4 mm had been used, in conjunction with the presence of colon wall nodularity, accordion sign, peri-colonic stranding, or otherwise unexplained ascites.

10) Ultrasound may be useful in critically ill patients suspected to have pseudomembranous colitis who cannot be transported for CT scan (Recommendation 2 C).

Point-of-care ultrasound may be useful in diagnosing and managing critically ill patients who cannot be moved to the radiology department [151].

Ultrasound findings of pseudomembranous colitis in severe cases include a thickened colonic wall with heterogeneous echogenicity and narrowing of the colonic lumen [152]. Pseudomembranes can also be visualised as hyperechoic lines covering the mucosa [152–155].

In the early stages of pseudomembranous colitis, the texture of the colonic wall is preserved. The hypoechoic edematous mucosa and muscularis propria may be thickened with the echogenic submucosa sandwiched between them. The presence of submucosal gaps may indicate extension of tissue damage into deeper structures. Intraperitoneal free fluid is seen in more than 70 % of cases [153–155].

11) Flexible sigmoidoscopy may be helpful for the diagnosis of *C. difficile* colitis (CDC) when there is a high level of clinical suspicion for *C. difficile* despite repeated negative laboratory assays (Recommendation 2 B).

Endoscopy should be used sparingly to confirm the diagnosis of *C. difficile* colitis since the diagnosis can be usually made by laboratory tests, clinical findings and imaging. Moreover colonoscopy may be hazardous in the setting of fulminant colitis where there may be increased risk of perforation [156].

A study by Johal et al. [157] described the use of flexible sigmoidoscopy as a tool for the diagnosis of *C. difficile* colitis when stool assays were negative. Of 136 patients with *C. difficile* associated diarrhea (CDAD) 56 patients had pseudomembranous colitis at sigmoidoscopy. The stool *C. difficile* cytotoxin test was negative in 29 (52 %) but toxigenic *C. difficile* was isolated from all of nine stool samples cultured. Of patients with pseudomembranous colitis,

30.4 % relapsed over the subsequent 57.7 days. The authors concluded that sigmoidoscopy should be considered in all hospitalised patients with diarrhea in whom the stool tests for *C. difficile* cytotoxin and enteric pathogens are negative.

Emergency colonoscopy or sigmoidoscopy may also reveal pseudomembranous colitis in patients too ill to wait for laboratory results.

Antimicrobial therapy

12) Unnecessary antimicrobial agent(s) and proton pump inhibitors should be discontinued if CDI is suspected (Recommendation 1 C).

13) Empirical therapy for CDI should be avoided unless there is a strong suspicion for CDI. If a patient has a strong suspicion for CDI, empirical therapy for CDI should be considered while awaiting test results (Recommendation 1 B).

In cases of suspected severe CDI, antimicrobial agent(s) should be discontinued, if possible [158].

A meta-analysis addressing factors associated with prolonged symptoms and severe disease due to *Clostridium difficile* showed that continued use of antimicrobials for infections other than CDI is significantly associated with an increased risk of CDI recurrence [159].

When antimicrobial therapy is indicated for symptomatic cases with a positive *C. difficile* toxin result, options include metronidazole, oral or intraluminal vancomycin and fidaxomicin [160–166].

14) Metronidazole is recommended for the treatment of mild-moderate disease (Recommendation 1 A).

Given at a dose of 500 mg orally 3 times a day for 10 days, metronidazole has been shown to be an inexpensive and effective treatment of non-severe CDI [167]. Metronidazole can also be administered intravenously with or without intraluminal vancomycin in patients unable to take oral medication e.g. those with post-surgical ileus.

A Cochrane analysis published in 2011 [167] reviewed 15 studies on the antibiotic treatment for CDI in adults. In three randomized controlled trials comparing symptomatic cure between metronidazole and vancomycin, no statistically significant difference was found [167]. Symptomatic cure was achieved in 79 % of patients who received vancomycin compared with 71 % of patients who received metronidazole (three studies; 335 patients; RR 0.91; 95 % CI 0.81–1.03, p 0.14).

15) Oral vancomycin is recommended for treatment of patients with severe disease, or for patients with mild-moderate disease who do not respond to metronidazole. (Recommendation 1 A).

Vancomycin orally 125 mg four times daily for 10 days is considered superior to metronidazole in severe *C. difficile* disease [168–170]. This may reflect the superior

pharmacokinetic properties of vancomycin which is concentrated in the gut lumen. Doses of up to 500 mg have been used in some patients with severe CDI [7] although there is little evidence for this in the literature.

16) In patients in whom oral antibiotics cannot reach the colon, vancomycin may be administered by enema and metronidazole can be given intravenously (Recommendation 1 B).

Intravenous vancomycin has no effect on CDI since the antibiotic is not excreted into the colon. Vancomycin enema may be an effective therapy for patients who cannot tolerate the oral preparation or patients with ileus who have delayed passage of oral antibiotics from the stomach to the colon. Trans-stoma vancomycin may also be effective in surgical patients with Hartmann resection, ileostomy, or colon diversion. A single-hospital, retrospective chart review on 47 consecutive patients with *C. difficile* colitis treated with intra-colonic vancomycin (ICV) was published by Kim PK et al. in 2013 [171]. Thirty-three of 47 patients (70 %) with severe *C. difficile* colitis responded to adjunct ICV with complete resolution without surgery. Multivariable analysis suggested that failures to intra-colonic vancomycin enemas occurred in patients who were older and frail with albumin < 2.5 g/dl and early surgery should be considered for those patients. Early surgery should also be offered to those patients who are failing maximal medical therapy that include ICV enemas.

17) Fidaxomicin may be used to treat CDI, especially in the patients at higher risk for recurrence (e.g. elderly patients with severe underlying disease or those requiring receiving concomitant antibiotics) (Recommendation 1 A).

Fidaxomicin orally 200 mg twice daily for 10 days may be an alternative to vancomycin in some patients with CDI [172, 173].

Fidaxomicin was non-inferior to vancomycin for initial cure of CDI in two prospective trials [164, 165]. In a first double-blind, randomized, non-inferiority trial [164] 629 adults with acute symptoms of *C. difficile* infection and a positive result on a stool toxin test were enrolled and randomly assigned to receive fidaxomicin (200 mg twice daily) or vancomycin (125 mg four times daily) orally for 10 days. The rates of clinical cure with fidaxomicin were non-inferior to those with vancomycin in both the modified intention-to-treat analysis (88.2 % with fidaxomicin and 85.8 % with vancomycin) and the per-protocol analysis (92.1 % and 89.8 %, respectively). Significantly fewer patients in the fidaxomicin group than in the vancomycin group had a recurrence of the infection, in both the modified intention-to-treat analysis and the per-protocol analysis. In a second multi-centre, double-blind, randomized, non-inferiority trial [165] 535 patients, 16 years or older with acute, toxin-positive

C. difficile infection were randomly allocated (1:1) to receive oral fidaxomicin (200 mg every 12 h) or oral vancomycin (125 mg every 6 h) for 10 days. Non-inferiority was shown for both the modified intention-to-treat analysis (15.4 % vs. 25.3 %, $P = 0.005$) and the per-protocol analysis (13.3 % vs. 24.0 %, $P = 0.004$). Patients receiving concomitant antibiotics for other infections had a higher cure rate with fidaxomicin (46 [90.2 %] of 51) than with vancomycin (33 [73.3 %] of 45; $p = 0.031$). Fidaxomicin may be useful for treating patients who are considered at high risk for recurrence (elderly patients with multiple comorbidities who are receiving concomitant antibiotics). However, it is important to note that there are no data available on the efficacy of Fidaxomicin in severe life-threatening disease.

The use of other antibiotics such as tigecycline [174, 175] fusidic acid, teicoplanin, rifamixin [167] and nitazoxanide [176], has been described in the literature, but they are not currently recommended for general use.

Surgical management

Patients with fulminant colitis (FC) who progress to systemic toxicity require surgical intervention.

To determine clinical predictors for the development of fulminant colitis in patients with CDI a 10-year retrospective review of FC patients who underwent colectomy was performed and compared with randomly selected age- and sex-matched non-fulminant CDI patients at a single institution study by Girotra in 2012 [177]. Predictive clinical and laboratory features included: old age (>70 years), prior CDI, profound leukocytosis (>18,000/mm³), hemodynamic instability, use of anti-peristaltic medications, and a clinical triad of increasing abdominal pain, distention and diarrhea.

18) Patients with severe CDI who progress to systemic toxicity should undergo early surgical consultation and evaluated for potential surgical intervention (Recommendation 1 C).

Patients with severe CDI who progress to systemic toxicity are likely to have serious comorbidities. Delaying surgery in this group leads to increased likelihood of adverse outcomes [178], although some reports show that a short period of medical optimization can improve outcomes before colectomy [179].

There are no reliable clinical and/or laboratory findings that can predict those patients who will respond to medical therapy and those who will subsequently need surgery [180].

Data comparing mortality rates between surgical and medical treatment for fulminant *C. difficile* colitis were published in a recent systematic review by Stewart et al. [181]. Five hundred and ten patients with FC were identified in six studies. Emergency colectomy for patients

with FC provided a survival advantage compared with continuing antibiotics. When all six studies numbering 510 patients were analysed, the pooled adjusted odds ratio of mortality comparing surgery with medical therapy, and weighted by the contribution of each study, was 0.70 (0.49–0.99) leading the authors to conclude that emergency colectomy has a therapeutic role in treating complicated *C. difficile* colitis.

Patients presenting with organ failure (acute renal failure, mental status changes, or cardiopulmonary compromise) also need prompt intervention.

The timing of surgical intervention is the key for survival of patients with FC [182–185].

Seder et al. [186] described 6,841 patients with CDI and showed a decreased mortality associated with surgery performed before the need for vasopressor requirement, especially in the patients <65 years old. Hall et al. [184] reviewed 3,237 consecutive cases of CDI and showed an increased mortality rate when surgical exploration was performed after intubation or the development of respiratory failure and the use of vasopressors.

Recently a risk scoring system (RSS) for daily clinical practice was designed by van der Wilden et al. [187]. Age greater than 70 years was assigned 2 points, white blood cell count equal to or greater than $20,000 \times 10^9/L$ or equal to or less than $2,000 \times 10^9/L$ was assigned 1 point, cardiorespiratory failure was assigned 7 points, and diffuse abdominal tenderness on physical examination was assigned 6 points. A value of 6 points was determined to be the threshold for reliably dividing low-risk (<6) from high-risk (≥ 6) patients. Only patients with cardiorespiratory failure or diffuse abdominal tenderness were high risk.

Ferrada et al. [188] reviewed the existing literature on the treatment of CDI and published practice management guidelines (PMG) for the Eastern Association for the Surgery of Trauma (EAST). The authors strongly recommended, that adult patients with CDI undergo early surgery before developing shock and the need for vasopressors. Although timing remains controversial Ferrada et al. found that it was between 3 days and 5 days after diagnosis in patients who are worsening or not clinically improving [188].

Many factors have been described as predictors of mortality in patients who undergo emergency intervention.

Sailhamer et al. [189] reviewed the records of 4796 inpatients diagnosed with *C. difficile* colitis. In 199 patients (4.1 %) with fulminant *C. difficile* colitis the in-hospital mortality rate was 34.7 %. Independent predictors of mortality included age 70 years or older, severe leukocytosis or leukopenia (white blood cell count, $\geq 35,000 \times 10^9/L$ or $<4000 \times 10^9/L$) or bacteremia (neutrophil bands, ≥ 10 %), and cardiorespiratory failure (intubation or vasopressors). Survival rates

were higher in patients who were cared for by surgical vs nonsurgical departments.

The ACS-NSQIP database from 2005 to 2010 was used by Lee et al. to study emergency open colectomies performed for *C. difficile* colitis in the USA [190]. The overall mortality was 33 % (111/335). Age 80 years or older, preoperative dialysis dependence, chronic obstructive pulmonary disease, and wound class III were associated high patient mortality. Thrombocytopenia (platelet count $<150 \times 10^3/mm^3$), coagulopathy (International Normalized Ratio >2.0), and renal insufficiency (blood urea nitrogen >40 mg/dL) were also associated with a higher mortality.

A systematic review and meta-analysis of outcomes following emergency surgery for *C. difficile* colitis was published by Banghu et al. [191]. Thirty-one studies were included, which presented data for 1433 patients undergoing emergency surgery for *C. difficile* colitis. It concluded that the strongest predictors for postoperative death were those relating to preoperative physiological status: preoperative intubation, acute renal failure, multiple organ failure and shock requiring vasopressors.

19) Resection of the entire colon should be considered to treat patients with fulminant colitis (FC) (Recommendation 1 B).

20) Diverting loop ileostomy with colonic lavage may be a useful alternative to resection of entire colon (Recommendation 2 C).

21) Patients with FC should be treated with high dose oral or by enema vancomycin (500 mg, 6 hourly) in combination with intravenous metronidazole (500 mg, 8 hourly). (Recommendation 1 C).

In the Banghu et al. meta-analysis [191] the most commonly performed operation for treatment of FC was total colectomy with end ileostomy (89 %, 1247/1401). When total colectomy with end ileostomy was not performed, reoperation to resect further bowel was needed in 15.9 % (20/ 126). In the recent meta-analysis by Ferrada et al. [188], 17 studies comparing colectomy versus other procedures or no surgery as treatment for CDI were analyzed. The authors recommended that total colectomy (vs. partial colectomy or other surgery) is the procedure of choice for patients with *C. difficile* colitis.

To evaluate the role of emergency colectomy in patients with FC, and to identify subgroups of patients that may benefit Lemontagne et al. [192] published a retrospective observational cohort study of 165 cases of FC that required ICU admission or prolongation of ICU stay in 2 tertiary care hospitals of Quebec, Canada. Eighty-seven (53 %) cases died within 30 days of ICU admission, of which almost half (38 of 87, 44 %) died within 48 h of ICU admission. The independent predictors of 30-day mortality were leukocytosis $\geq 50 \times 10^9/L$, lactate ≥ 5 mmol/L, age ≥ 75 years, immunosuppression and

shock requiring vasopressors. Patients who underwent an emergency colectomy were less likely to die than those treated medically. Colectomy was more beneficial in patients aged 65 years or more, in immunocompetent patients and in patients with a leukocytosis $> \text{or} = 20 \times 10^9/\text{L}$ or lactate between 2.2 and 4.9 mmol/L.

Diverting loop ileostomy with antegrade colonic lavage may be a colon preserving alternative to total colectomy [193, 194]. To evaluate whether a minimally invasive, colon-preserving approach may be an alternative to subtotal colectomy in the treatment of FC, a historical control group study was performed at the University of Pittsburgh Medical Center or and the Veterans' Administration Healthcare System, Pittsburgh between June 2009 and January 2011 [193]. All patients with FC were managed by a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol 3350/electrolyte solution via the ileostomy and postoperative antegrade instillation of vancomycin flushes via the ileostomy. Forty-two patients were treated during this time period. There was no significant difference in age, sex, pharmacologic immunosuppression, and Acute Physiology and Chronic Health Evaluation-II scores between the studied cohort and historical controls. The operation was accomplished laparoscopically in 35 patients (83 %). This treatment strategy resulted in reduced mortality compared to their historical population. Preservation of the colon was achieved in 39 of 42 patients (93 %). Of note, in this study vancomycin antegrade enemas were continued via the ileostomy every 6 h for 10 days after ileostomy formation and this likely augmented the effect of the defunctioning surgery.

Supportive care

22) Supportive measures, including intravenous fluid resuscitation and electrolyte replacement, should be provided to all patients with severe *C. difficile* infection (Recommendation 1 C).

Diarrhea results in significant volume depletion and electrolyte abnormalities, and fluid and electrolyte imbalance should be promptly corrected [119, 120].

23) Early detection of shock and aggressive management of underlying organ dysfunction are essential for optimum outcomes in patients with fulminant colitis (Recommendation 1 C).

Early detection and prompt aggressive treatment of the underlying organ dysfunction is an essential component of improving outcome of critical ill patients [120].

Severe CDI may present with a fulminant course and may be associated with great morbidity and high mortality. Physiologic support including close invasive monitoring in an intensive care unit setting and aggressive resuscitation are often necessary in fulminant colitis.

Recurrent *C. difficile* infection (RCDI)

Recurrence is diagnosed when CDI recurs < 8 weeks after the onset of a previous episode, provided the symptoms from the previous episode resolved after completion of initial treatment and other causes have been excluded. Symptomatic recurrent *C. difficile* infection (RCDI) occurs in approximately 20 % of patients and is challenging to treat [195]. Patients with recurrence of CDI should therefore be treated by clinicians who have experience in treating the infection.

24) Agents that may be used to treat the first recurrence of CDI include metronidazole, for non-severe RCDI, and vancomycin for severe RCDI. (Recommendation 1 B).

25) Fidaxomicin may be used as an alternative agent (Recommendation 1 B).

A systematic review on the treatment of RCDI was recently published [196]. Metronidazole and vancomycin have a good evidence base for use in RCDI but heterogeneity in treatment duration and treatment doses between the studies precluded robust conclusions. Fidaxomicin may also have a role in the treatment of first recurrence. Fidaxomicin was superior to vancomycin in terms of recurrences, with significantly less recurrence at 28 days. This was confirmed in some subgroup analysis [197].

26) In subsequent recurrence of CDI (2nd or later) oral vancomycin or fidaxomicin is recommended (Recommendation 1 B).

Vancomycin and fidaxomicin are equally effective in resolving CDI symptoms but fidaxomicin has been shown to be associated with a lower likelihood of CDI recurrence after a first recurrence [164, 165, 197]. However, there are no prospective randomized controlled trials investigating the efficacy of fidaxomicin in patients with multiple recurrences of CDI. Vancomycin is often administered using a prolonged tapered and/or pulsed regimen which may be more effective than a standard 10 to 14 day course although no RCTs have been reported [198].

Probiotics

27) Probiotics may be considered as an adjunctive treatment to antibiotics for immunocompetent patients with RCDI (Recommendation 2 B).

Little evidence exists to support the use of probiotics in the first episode of CDI [116]. Two randomized controlled trials showed some effectiveness for *Saccharomyces boulardii* CNCM I-745 in recurrent CDI. The first demonstrated a lower relapse rate compared with a placebo control group (35 vs 65 % in the placebo group) [199] and the second found that the combination of *S. boulardii* (1 g/d) with high dose vancomycin (2 g/d) was more effective than high dose vancomycin and placebo (17 vs 50 % recurrence rate) [200]. Other studies with

Lactobacillus strains (*L. rhamnosus* GG or *L. plantarum* 299v) were stopped prematurely due to enrollment problems [201]. Probiotics should not be administered to patients at risk of bacteraemia or fungaemia [116].

There is limited evidence to support the use of probiotics for the primary prevention of CDI from developing. A meta-analysis of 11 studies was published in 2012 [202]. Two studies showed significantly lower rates of CDI among the probiotic recipients. A meta-analysis of three studies that used the probiotic combination *Lactobacillus acidophilus* CL1285 and *Lactobacillus casei* LBC80R and a combined analysis of those studies with four studies that used *Saccharomyces boulardii*, showed lower CDI rates in recipients of probiotics compared with recipients of placebo (risk ratio = 0.39; 95 % confidence interval 0.19–0.79). However, given the potential risk of bloodstream infection with these organisms further studies are warranted before their use can be recommended routinely.

Faecal microbiota transplantation

28) Intestinal or faecal microbiota transplantation (IMT or FMT) may be an effective option for the treatment of RCDI (Recommendation 1 B).

Intestinal or faecal microbiota transplantation (IMT or FMT) has been considered as an alternative therapy to treat RCDI [203–208]. It involves infusing intestinal microorganisms (in a suspension of healthy donor stool) into the intestine of patients to restore the intestinal microbiota.

The rationale of FMT is that disruption of the normal balance of colonic flora allows *C. difficile* strains to grow and produce CDI. By reintroducing normal flora via donor faeces, the imbalance may be corrected, and normal bowel function re-established [203].

FMT has not been widely adopted as a therapeutic tool probably due to concerns regarding safety and acceptability [204].

A systematic literature review of IMT treatment for RCDI and pseudomembranous colitis was published in 2011 by Gough et al. [205]. In 317 patients treated across 27 case series and reports, IMT was highly effective, showing disease resolution in 92 % of cases. In those studies, 35 % of patients received IMT via enema, with a response rate of 95; 23 % patients received IMT via naso-jejunal tube by gastroscop, with a response rate of 76; and 19 % via colonoscopy, with a response rate of 89 %. Effectiveness varied by route of instillation, relationship to stool donor, volume of IMT given, and treatment before infusion.

Recently a systematic review was published by Cammarota et al. [206]. Twenty full-text case series, 15 case reports, and 1 randomized controlled study were included for the final analysis. Almost all patients treated

with donors' fecal infusion experienced recurrent episodes of CD-associated diarrhea despite standard antibiotic treatment. Of a total of 536 patients treated, 467 (87 %) experienced resolution of diarrhea. Diarrhea resolution rates varied according to the site of infusion: 81 % in the stomach; 86 % in the duodenum/jejunum; 93 % in the cecum/ascending colon; and 84 % in the distal colon. No severe adverse events were reported with the procedure.

In a recently published randomized clinical trial by van Nood et al. [208] patients with RCDI were randomized to three groups; 1) vancomycin regime only; 2) vancomycin with duodenal infused FMT and 3) vancomycin and bowel lavage. In the FMT treated group an 81% reduction in diarrhoea was observed. The FMT group were observed to have normalization of their intestinal bacterial composition which was similar to that of the donor. Although, this trial has shown exciting results, these need to be interpreted with caution as the trial included only small number of patients, was not blinded, and was aborted early due to profound differences in the groups. It has also been criticised for potentially having several potential biases.

FMT may be administered via enemas or as a slurry given via a nasogastric tube. In the fall of 2014, Youngster et al. [209] reported their experience on utilizing frozen FMT capsules in 20 patients who had RCDI. Fourteen patients (70 %) had resolution of diarrhea after the first treatment, and an additional 4 patients responded after a second treatment, for a clinical resolution rate of 90 %.

29) FMT may be effective in immunocompromised patients and patients who have had solid organ transplants (Recommendation 2 B).

Patients who are immunocompromised are at increased risk of CDI. During the last two years the first data on FMT in immunocompromised patients began to appear in the medical literature [210].

A multicenter retrospective series on the use of FMT in immunocompromised (IC) patients with CDI that was recurrent, refractory, or severe was published in 2014 [211]. Reasons for IC included: HIV/AIDS (3), solid organ transplant (19), oncologic condition (7), immunosuppressive therapy for inflammatory bowel disease (IBD; 36), and other medical conditions/medications (15).

This series demonstrated the effective use of FMT for CDI in IC patients with few serious adverse events or related adverse events.

Intravenous immunoglobulin (IVIG)

30) IVIG should only be used as adjunct therapy in patients with multiple recurrent or fulminant CDI until results from large, randomized controlled trials are available (Recommendation 2 C).

IVIG treatment has been proposed based on the evidence that the level of immune response to *C. difficile* colonization is a major determinant of magnitude and duration of clinical manifestations. Passive immunization with IVIG has been reported to be successful in several small series. A review by Abourgergi [212] of fifteen small, mostly retrospective and non-randomized studies documented success with IVIG in the treatment of protracted, recurrent, or severe CDI. The authors concluded IVIG should only be used as adjunct therapy until results from large, randomized controlled trials are available.

Monoclonal antibodies

31) Infusion with monoclonal antibodies may be of use to prevent recurrences of CDI, particularly in patients with CDI due to the 027 epidemic strain (Recommendation 2 C).

In a phase II clinical trial [213], the use of monoclonal antibodies to toxins A and B as an adjunct to antibiotics was shown to decrease recurrence rates in patients with CDI compared with placebo (7 vs. 25 % respectively; 95 % confidence interval, 7 to 29; $P < 0.001$). The recurrence rates among patients with the epidemic BI/NAP1/027 strain were 8 % for the antibody group compared with 32 % for placebo ($P = 0.06$); among patients with more than one previous episode of CDI, recurrence rates were 7 and 38 %, respectively ($P = 0.006$). The authors concluded that the addition of monoclonal antibodies against *C. difficile* toxins to antibiotic agents significantly reduced the recurrence of *C. difficile* infection. The findings of this study require confirmation before firm recommendations can be made.

Enteral nutrition in CDI

32) Tube feeding patients should be clinically assessed due to their risk for developing CDI (Recommendation 2 C).

It is widely accepted that enteral nutrition (EN) maintains gut mucosal integrity which leads to decreased intestinal permeability, decreased infections, and an improved immunological status. EN during episodes of diarrhea may be well tolerated and may improve enterocyte healing and maintenance of enzyme activity [214, 215]. EN, however, has also been associated with increased risk of CDI [216]. Bliss, et al. evaluated 76 tube-fed and non tube-fed hospital patients for the development of CDI [217]. Patients were controlled for age, severity of illness and duration of hospitalization. Patients who were tube-fed were statistically more likely to develop *C. difficile* associated diarrhea (20 versus 8 % $p = 0.03$). One of the reasons may be prolonged use of elemental diets. It is known that critically ill patients tolerate feeding well if the feed is given in elemental form and delivered beyond the stomach into the jejunum because it is totally absorbed within the upper

small intestine [218]. Elemental diets are completely absorbed within the small intestine and therefore deprive the colonic microbiota of their source of nutrition, such as dietary fiber, fructose oligosaccharides, and resistant starch [219]. The resultant suppression of colonic fermentation may therefore lead to the disruption of the normal gut flora and the creation of a “permissive” environment for *C. difficile* colonization and subsequent infection. In feeding tube patients the conversion of elemental diet feeding to a diet containing adequate indigestible carbohydrate after the first week of critical illness may, in theory, be useful.

Recently, Puri et al. [220] reported that daily concomitant treatment with 4 g cholestyramine in patients receiving long-term intravenous ceftriaxone (2 to 4 g ceftriaxone daily, for an average of >10 weeks) was associated with CDI in only three out of 46 patients (6.5 %) compared with 23.1 % of those receiving ceftriaxone alone [221]. Cholestyramine (or colestyramine) is a hydrophilic, water insoluble, non-digestible basic anion-exchange resin which can bind luminal TcdA and TcdB.

Studies have also investigated the possible value of exogenous Phosphatidylcholine (PC) administration for reinforcement of the mucus layer [222, 223]. Mucus or “exogenous” mucus in the form of PC may have a synergistic role with secretory IgA as a barrier against *C. difficile* toxin A though additional studies are needed to demonstrate its clinical benefit before recommendations can be made [222, 223].

Anti-motility agents

33) The use of anti-peristaltic agents for the treatment of CDI should be discouraged. If anti-peristaltic, if used in isolation agents, are used to control persistent symptoms in patients with CDI they must always be accompanied by medical therapy (Recommendation 2 C).

A review of the literature regarding anti-motility treatment of CDI found 55 patients with CDI who were exposed to anti-motility agents [224].

Nine patients (16 %) died, and 27 patients (49 %) had unknown outcomes. Seventeen patients (31 %) with CDI developed colonic dilation; 5 of these patients with severe CDI died. However, all patients who experienced complications or died were given anti-motility agents alone initially, without an appropriate antibiotic and 23 patients who received metronidazole or vancomycin co-administered with the anti-motility agent experienced no complications. Further study of the role of anti-motility agents in providing symptomatic relief and reducing environmental contamination with infectious stool may be warranted though, until there is clear evidence of benefit, their use in patients with CDI should be avoided [116].

Prevention

34) Proper antimicrobial stewardship in selecting an appropriate antibiotic and optimizing its dose and duration to cure an infection may prevent the emergence of *C. difficile* (Recommendation 1 B).

Despite vigorous infection control measures until recently, CDI was causing an increasing problem in healthcare facilities worldwide. As CDI is thought to follow disruption to the normal bacterial flora of the colon occurring as a consequence of antibiotic use [225], it is logical that antibiotic stewardship programs may be useful in preventing CDI [226]. Good antimicrobial stewardship involves ensuring appropriate antibiotic choice and optimizing antibiotic dose and duration to cure an infection while minimizing toxicity and conditions conducive to CDI. Recently, a systematic review [227] of interventions to improve antibiotic prescribing practices for hospital inpatients suggested that reducing excessive antibiotic prescribing can prevent hospital-acquired infections and that interventions to increase effective prescribing improve clinical outcome. It would appear that cephalosporin and quinolone antibiotics may be particularly high risk, in this context [116, 228].

35) Patients with suspected or proven CDI should be placed in contact (enteric) precautions (Recommendation 1 B).

Prompt identification of patients with symptomatic CDI is essential so that appropriate isolation precautions can be put into effect.

This is particularly important in reducing environmental contamination as spores can survive for months in the environment [229], despite regular use of environmental cleaning agents.

Contact (enteric) precautions patients with CDI should be maintained until the resolution of diarrhea, which is demonstrated by passage of formed stool for at least 48 h. Patients with known or suspected CDI should ideally be placed in a private room [116, 230] with ensuite hand washing and toilet facilities. If a private room is not available known CDI patients may be cohort nursed in the same area [231] though the theoretical risk of transfection with different strains exists.

This is supported by a retrospective cohort of 2859 patients by Chang et al. [232]. Patients who were roommates or neighbors of a patient with CDI were at risk of nosocomial acquisition of CDI (RR, 3.94; 95 % CI, 1.27–12.24).

36) Hand hygiene with soap and water is a cornerstone of the prevention of *C. difficile*. Hand hygiene, contact precautions and good cleaning and disinfection of the environment and patient care equipment, should be used by all health-care workers contacting

any patient with known or suspected CDI (Recommendation 1 B).

Hand hygiene with soap and water and the use of contact precautions along with good cleaning and disinfection of the environment and patient equipment, should be used by all health-care workers contacting any patient with known or suspected CDI. Hand hygiene is a cornerstone of prevention of nosocomial infections, including *C. difficile*. Alcohol-based hand sanitizers are highly effective against non-spore-forming organisms, but they may not kill *C. difficile* spores or remove *C. difficile* from the hands [233, 234].

The most effective way to remove them from hands is through hand washing with soap and water.

For environmental cleaning, hypochlorite disinfection such as sodium hypochlorite solutions are suggested for regular use in patient areas where *C. difficile* transmission is ongoing [231].

Though disposable glove use during care of a patient with CDI may be effective in preventing the transmission of *C. difficile* [230], these must be removed at the point of use and hands thoroughly decontaminated afterwards through soap and water hand washing.

Abbreviations

CDI: *C. difficile* infection; RCDI: Recurrent *C. difficile* infection; FC: Fulminant colitis.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MS wrote the manuscript. All Authors reviewed the manuscript and approved the final manuscript.

Author details

¹Department of Surgery, Macerata Hospital, Via Santa Lucia 2, 62019 Macerata, Italy. ²American Board of Surgery, Philadelphia, USA. ³Department of Surgery, College of Medicine and Health Sciences, UAE University, Al-Ain, United Arab Emirates. ⁴Department of Surgery, Queen Elizabeth Hospital, Birmingham, UK. ⁵2nd Infectious Diseases Division, National Institute for Infectious Diseases L. Spallanzani, Rome, Italy. ⁶Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Washington, USA. ⁷Department of Medical Microbiology, King's College Hospital, London, UK. ⁸Department of Surgery, Tan Tock Seng Hospital, Singapore. ⁹Emergency Surgery, and Surgical Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ¹⁰Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. ¹¹Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. ¹²Department of Surgery, University of Michigan, Ann Arbor, MI, USA. ¹³Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI, USA. ¹⁴General Surgery I, Papa Giovanni XXIII Hospital, Bergamo, Italy. ¹⁵Department of Surgery, University Hospital Center Zagreb and School of Medicine, University of Zagreb, Zagreb, Croatia. ¹⁶Trauma and Acute Care Surgery Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel. ¹⁷UHLIN (Unité d'Hygiène et de Lutte contre les Infections Nosocomiales) National Reference Laboratory for Clostridium difficile Groupe Hospitalier de l'Est Parisien (HUEP), Paris, France. ¹⁸Department of General Surgery, Rambam Health Care Campus, Haifa, Israel. ¹⁹Academic Department of Surgery, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK. ²⁰Department of Surgery, University of Colorado, Denver Health Medical Center, Denver, USA. ²¹Pathology and Laboratory Medicine, VA Boston Healthcare System, West Roxbury MA and BU School of Medicine, Boston, MA, USA. ²²Department of Internal Medicine, University Hospital, Dr. José E. González, Monterrey, Mexico. ²³Department of Surgery, University of Santiago de Compostela, Santiago de Compostela, Spain. ²⁴Department of Pathology, University of Alberta Edmonton,

Edmonton, AB, Canada. ²⁵Emergency Surgery Department, Maggiore Parma Hospital, Parma, Italy. ²⁶Department of General Surgery, Medway Maritime Hospital, Gillingham Kent, UK. ²⁷Department of Surgery, Division of Acute Care Surgery, University of Michigan, Ann Arbor, MI, USA. ²⁸Department of Surgery, Northeast Ohio Medical University, Summa Akron City Hospital, Akron, OH, USA. ²⁹Faculty of Medicine, Transilvania University, Infectious Diseases Hospital, Brasov, Romania. ³⁰Division of Trauma, Surgical Critical Care, Burns, and Acute Care Surgery, University of California San Diego Health Science, San Diego, USA. ³¹Division of Acute Care Surgery, Trauma and Surgical Critical Care, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. ³²Department of Surgery, Tianjin Nankai Hospital, Nankai Clinical School of Medicine, Tianjin Medical University, Tianjin, China. ³³Department of Infectious Diseases, Jagiellonian University, Medical College, Kraków, Poland. ³⁴Department of General Surgery, Adana Numune Training and Research Hospital, Adana, Turkey. ³⁵Department of Surgery, Tbilisi State Medical University, Kipshidze Central University Hospital, Tbilisi, Georgia. ³⁶Department of Surgery, Hamad General Hospital, Doha, Qatar. ³⁷Trauma Surgery Unit, Maggiore Hospital, Bologna, Italy. ³⁸Clinical Infectious Diseases Hospital, Ovidius University, Constanta, Romania. ³⁹National Reference Laboratory for *Clostridium difficile*, AP-HP, Saint-Antoine Hospital, Paris, France. ⁴⁰Department of General, Visceral and Thoracic Surgery, Klinikum Peine, Hospital of Medical University Hannover, Peine, Germany. ⁴¹Vital Care, Inc, Meridian, MS, USA. ⁴²Department of Medicine, Section of Infectious Diseases, King Fahad Medical City, Riyadh, Saudi Arabia. ⁴³Department of General Surgery, Trauma and Emergency Surgery Division, ABC Medical School, Santo André, SP, Brazil. ⁴⁴Division of Trauma, Critical Care and Emergency Surgery, Virginia Commonwealth University, Richmond, VA, USA. ⁴⁵Department of Surgery, Stanford University, Stanford, CA, USA. ⁴⁶Division of Trauma Surgery, Hospital de Clinicas, School of Medical Sciences, University of Campinas, Campinas, Brazil. ⁴⁷Service of Gastroenterology and Hepatology, Geneva University Hospital, Genève, Switzerland. ⁴⁸Critical Care Unit, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), A Coruña, Spain. ⁴⁹Department of Surgery Mansoura, Faculty of Medicine, Mansoura University, Mansoura, Egypt. ⁵⁰Surgery Department, Hospital Universitario (HU) Terezinha de Jesus da Faculdade de Ciências Médicas e da Saúde de Juiz de Fora (SUPREMA), Hospital Universitario (HU) Universidade Federal de Juiz de Fora (UFJF), Juiz de Fora, Brazil. ⁵¹Department of Internal Medicine, Pinnacle Health Hospital, Harrisburg, PA, USA. ⁵²Department of Medicine, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, Buckinghamshire, UK. ⁵³Department of Surgery, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany. ⁵⁴Department of Gastroenterology and Hepatology, Ochsner Clinic Foundation, New Orleans, LA, USA. ⁵⁵Department of Surgery, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea. ⁵⁶General Surgery Department, Erzincan University Mengücek Gazi Training and Research Hospital, Erzincan, Turkey. ⁵⁷School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia. ⁵⁸Department of Pharmacy Practice, St Louis College of Pharmacy, St Louis, MO, USA. ⁵⁹Research School of Population Health, The Australian National University, Acton, ACT, Australia. ⁶⁰Clinic For Emergency surgery, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade, Belgrade, Serbia. ⁶¹General and Trauma Surgery, Albert Einstein College of Medicine, North Bronx Healthcare Network, Bronx, NY, USA. ⁶²Division of Infectious Diseases, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. ⁶³Division of Critical Care & Trauma Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea. ⁶⁴Abdominal Center, Helsinki University Hospital Meilahti, Helsinki, Finland. ⁶⁵Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. ⁶⁶Department of Surgery, Post-Graduate Institute of Medical Sciences, Rohtak, India. ⁶⁷Department of Surgery, Washington University School of Medicine, Saint Louis, USA. ⁶⁸Department of Infectious Diseases and Clinical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Turkey. ⁶⁹Department of Surgery, University of Florida, Gainesville, FL, USA. ⁷⁰Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden. ⁷¹Department of Surgery, Fundación Valle del Lili, Hospital Universitario del Valle, Universidad del Valle, Cali, Colombia. ⁷²Emergency Surgery and Trauma Unit, Department of Surgery, Ribeirão Preto, Brazil. ⁷³Gastroenterology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. ⁷⁴Department of Medicine, Hammersmith Hospital and Imperial College London, London, UK. ⁷⁵Infectious Diseases and Microbiology Unit, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, Buckinghamshire, UK. ⁷⁶Department of Abdominal and General Surgery, General Hospital Jesenice, Jesenice, Slovenia. ⁷⁷Department of Surgery, Medical University of Plovdiv, Plovdiv, Bulgaria. ⁷⁸Division

of General Surgery and Organ Transplantation, Department of Surgery, Catholic University of the Sacred Heart, Rome, Italy. ⁷⁹Department of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome, Italy. ⁸⁰Department of Surgery, The Pennsylvania State University, College of Medicine, Hershey, PA, USA. ⁸¹Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France. ⁸²AP-HP Bichat hospital, Medical and infectious diseases ICU, Paris, France. ⁸³Emergency Medicine and Surgery, Macerata hospital, Macerata, Italy. ⁸⁴1st Surgical Clinic, University Hospital of St. Ann Brno, Brno, Czech Republic. ⁸⁵Department of Surgery, Radboud University Medical Center, Nijmegen, Netherlands. ⁸⁶Infection Prevention/Epidemiology, Providence Saint John's Health Center, Santa Monica, CA, USA. ⁸⁷Infection Control Unit, Angers University, CHU d'Angers, Angers, France. ⁸⁸Department of Surgery, Ancona University Hospital, Ancona, Italy. ⁸⁹Clinic of Infectious Diseases, St Orsola-Malpighi University Hospital, Bologna, Italy.

Received: 22 May 2015 Accepted: 12 August 2015

Published online: 20 August 2015

References

- Clements AC, Magalhães RJ, Tatem AJ, Paterson DL, Riley TV. *Clostridium difficile* PCR ribotype 027: assessing the risks of further worldwide spread. *Lancet Infect Dis*. 2010;10:395–404.
- Lessa FC, Gould CV, McDonald LC. Current status of *Clostridium difficile* infection epidemiology. *Clin Infect Dis*. 2012;55:65–70.
- Goudarzi M, Seyedjavadi SS, Goudarzi H, Mehdizadeh Aghdam E, Nazeri S. *Clostridium difficile* Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options. *Scientifica*. 2014;2014:916826.
- To KB, Napolitano LM. *Clostridium difficile* infection: update on diagnosis, epidemiology, and treatment strategies. *Surg Infect*. 2014;15:490–502.
- Eckmann C, Wasserman M, Latif F, Roberts G, Beriot-Mathiot A. Increased hospital length of stay attributable to *Clostridium difficile* infection in patients with four co-morbidities: an analysis of hospital episode statistics in four European countries. *Eur J Health Econ*. 2013;14(5):835–46.
- Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections. *Am J Gastroenterol*. 2013;108(4):478–98.
- Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for *Clostridium difficile* infection. *Clin Microbiol Infect*. 2014;20 Suppl 2:1–26.
- Zerey M, Paton BL, Lincourt AE, Gersin KS, Kercher KW, Heniford BT. The burden of *Clostridium difficile* in surgical patients in the United States. *Surg Infect*. 2007;8:557–66.
- Halabi WJ, Nguyen VQ, Carmichael JC, Pigazzi A, Stamos MJ, Mills S. *Clostridium difficile* colitis in the United States: a decade of trends, outcomes, risk factors for colectomy, and mortality after colectomy. *J Am Coll Surg*. 2013;217:802–12.
- Herzog T, Deleites C, Belyaev O, Chromik AM, Uhl W. *Clostridium difficile* in visceral surgery. *Chirurg*. 2014; Nov 30. [Epub ahead of print].
- Abdelsattar ZM, Krapohl G, Alrahmani L, Banerjee M, Krell RW, Wong SL, et al. Postoperative Burden of Hospital-Acquired *Clostridium difficile* Infection. *Infect Control Hosp Epidemiol*. 2015;36(1):40–6.
- Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an American College of Chest Physicians task force. *Chest*. 2006;129:174–81.
- Brozek JL, Akl EA, Jaeschke R, Lang DM, Bossuyt P, Glasziou P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. *Allergy*. 2009;64:1109–16.
- Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of *Clostridium difficile* isolates from various patient populations. *Gastroenterology*. 1981;81:5–9.
- Samore MH, DeGirolami PC, Tlucko A, Lichtenberg DA, Melvin ZA, Karchmer AW. *Clostridium difficile* colonization and diarrhea at a tertiary care hospital. *Clin Infect Dis*. 1994;18:181–7.
- Walker KJ, Gilliland SS, Vance-Bryan K, Moody JA, Larsson AJ, Rotschafer JC, et al. *Clostridium difficile* colonization in residents of long-term care facilities: prevalence and risk factors. *J Am Geriatr Soc*. 1993;41:940–6.
- Cheng AC, Ferguson JK, Richards MJ, Robson JM, Gilbert GL, McGregor A, et al. Australasian Society for Infections Diseases. Australasian Society for

- Infectious Diseases guidelines for the diagnosis and treatment of *Clostridium difficile* infection. *Med J Aust.* 2011;194:353–8.
18. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of *Clostridium difficile* infection. *N Engl J Med.* 1989;320:204–10.
 19. Shaughnessy MK, Micicelli RL, Depestel DD, Arndt J, Strachan CL, Welch KB, et al. Evaluation of hospital room assignment and acquisition of *Clostridium difficile* infection. *Infect Control Hosp Epidemiol.* 2011;32:201–6.
 20. Pruitt RN, Lacy DB. Toward a structural understanding of *Clostridium difficile* toxins A and B. *Front Cell Infect Microbiol.* 2012;2:28.
 21. Jank T, Gieseemann T, Aktories K. Rho-glucosylating *Clostridium difficile* Toxins A and B: new insights into structure and function. *Glycobiology.* 2007;17:15R–22.
 22. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in *Clostridium difficile* infection. *Nature.* 2010;467:711–3.
 23. Carter GP, Rood JJ, Lyras D. The role of toxin A and toxin B in the virulence of *Clostridium difficile*. *Trends Microbiol.* 2012;20:21–9.
 24. Kuehne SA, Coltery MM, Kelly ML, Cartman ST, Cockayne A, Minton NP. Importance of toxin A, toxin B, and CDT in virulence of an epidemic *Clostridium difficile* strain. *J Infect Dis.* 2014;209(1):83–6.
 25. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. *Lancet.* 2005;366(9491):1079–84.
 26. Eckert C, Coignard B, Hebert M, Tarnaud C, Tessier C, Lemire A, et al. ICD-Raisin Working Group. Clinical and microbiological features of *Clostridium difficile* infections in France: the ICD-RAISIN 2009 national survey. *Med Mal Infect.* 2013;43:67–74.
 27. Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E, Poxton I. European Study Group on *Clostridium difficile* (ESGCD). Prospective study of *Clostridium difficile* infections in Europe with phenotypic and genotypic characterisation of the isolates. *Clin Microbiol Infect.* 2007;13:1048–57.
 28. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al. *Clostridium difficile* infection in Europe: a hospital-based survey. *Lancet.* 2011;377:63–73.
 29. De Rosa FG, Cavallerio P, Corcione S, Parlato C, Fossati L, Serra R, et al. Molecular Characterization of Toxigenic *Clostridium difficile* in a Northern Italian Hospital. *Curr Microbiol.* 2015;70(2):154–5.
 30. Geric B, Johnson S, Gerding DN, Grabnar M, Rupnik M. Frequency of binary toxin genes among *Clostridium difficile* strains that do not produce large clostridial toxins. *J Clin Microbiol.* 2003;41:5227–32.
 31. Barth H. Uptake of binary actin ADP-ribosylating toxins. *Rev Physiol Biochem Pharmacol.* 2004;152:165–82.
 32. Bacci S, Mølbak K, Kjeldsen MK, Olsen KE. Binary toxin and death after *Clostridium difficile* infection. *Emerg Infect Dis.* 2011;17:976–82.
 33. Sundriyal A, Roberts AK, Ling R, McGlashan J, Shone CC, Acharya KR. Expression, purification and cell cytotoxicity of actin-modifying binary toxin from *Clostridium difficile*. *Protein Expr Purif.* 2010;74:42–8.
 34. Huber CA, Foster NF, Riley TV, Paterson DL. Challenges for standardization of *Clostridium difficile* typing methods. *J Clin Microbiol.* 2013;51:2810–4.
 35. Clements AC, Magalhaes RJ, Tatem AJ, Paterson DL, Riley TV. *C. difficile* PCR ribotype 027: assessing the risks of further worldwide spread. *Lancet Infect Dis.* 2010;10:395–404.
 36. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of *Clostridium difficile* infection. *Clin Infect Dis.* 2008;46:12–8.
 37. Lawrence J. Contemporary management of *Clostridium difficile* associated-disease. *Gastroenterol Endosc News Speed.* 2007;5:35–40.
 38. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for *Clostridium difficile* infection and colonization. *N Engl J Med.* 2011;365(18):1693–703.
 39. McFarland LV. Renewed interest in a difficult disease: *Clostridium difficile* infections—epidemiology and current treatment strategies. *Curr Opin Gastroenterol.* 2009;25:24–35.
 40. Vecchio AL, Zacur GM. *Clostridium difficile* infection: an update on epidemiology, risk factors, and therapeutic options. *Curr Opin Gastroenterol.* 2012;28:1–9.
 41. Furuya-Kanamori L, Stone JC, Clark J, McKenzie SJ, Yakob L, Paterson DL, et al. Comorbidities, Exposure to Medications, and the Risk of Community-Acquired *Clostridium difficile* Infection: A Systematic Review and Meta-analysis. *Infect Control Hosp Epidemiol.* 2015;36(2):132–41.
 42. Garey KW, Jiang ZD, Ghantaji S, Tam VH, Arora V, Dupont HL. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent *Clostridium difficile* infection. *Clin Infect Dis.* 2010;51(12):1406–10.
 43. Sanders NL, Bollinger RR, Lee R, Thomas S, Parker W. Appendectomy and *Clostridium difficile* colitis: relationships revealed by clinical observations and immunology. *World J Gastroenterol.* 2013;19(34):5607–14.
 44. Seretis C, Seretis F, Goonetilleke K. Appendectomy and *Clostridium difficile* infection: is there a link? *J Clin Med Res.* 2014;6(4):239–41.
 45. Clanton J, Subichin M, Drolshagen K, Daley T, Firstenberg MS. Fulminant *Clostridium difficile* infection: An association with prior appendectomy? *World J Gastrointest Surg.* 2013;5(8):233–8.
 46. Yong FA, Alvarado AM, Wang H, Tsai J, Estes NC. Appendectomy: a risk factor for colectomy in patients with *Clostridium difficile*. *Am J Surg.* 2014;17.
 47. Khanna S, Baddour LM, Dibaise JK, Pardi DS. Appendectomy is not associated with adverse outcomes in *Clostridium difficile* infection: a population-based study. *Am J Gastroenterol.* 2013;108(4):626–7.
 48. Huang H, Wu S, Chen R, Xu S, Fang H, Weintraub A, et al. Risk factors of *Clostridium difficile* infections among patients in a university hospital in Shanghai, China. *Anaerobe.* 2014;30:65–9.
 49. Walker AS, Eyre DW, Wyllie DH, Dingle KE, Harding RM, O'Connor L, et al. Characterisation of *Clostridium difficile* hospital ward-based transmission using extensive epidemiological data and molecular typing. *PLoS Med.* 2012;9(2), e1001172.
 50. Theriot CM, Young VB. Microbial and metabolic interactions between the gastrointestinal tract and *Clostridium difficile* infection. *Gut Microbes.* 2014;5(1):86–95.
 51. Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. *Nat Rev Immunol.* 2013;13(5):321–35.
 52. Pérez-Cobas AE, Artacho A, Ott SJ, Moya A, Gosalbes MJ, Latorre A. Structural and functional changes in the gut microbiota associated to *Clostridium difficile* infection. *Front Microbiol.* 2014;5:335.
 53. Kamada N, Chen GY, Inohara N, Núñez G. Control of pathogens and pathobionts by the gut microbiota. *Nat Immunol.* 2013;14(7):685–90.
 54. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for *Clostridium difficile* infection after exposure to antibiotics. *J Antimicrob Chemother.* 2012;67:742–8.
 55. Kazakova SV, Ware K, Baughman B, Bilukha O, Paradis A, Sears S, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of *Clostridium difficile*. *Arch Intern Med.* 2006;166:2518–24.
 56. Muto CA, Pokrywka M, Shutt K, Mendelshon AB, Nouri K, Posey K, et al. A large outbreak of *Clostridium difficile*-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. *Infect Control Hosp Epidemiol.* 2005;26:273–80.
 57. Loo VG, Poirier L, Miller MA, Oughton M, Libman MB, Michaud S, et al. A predominately clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med.* 2005;353:2442–9.
 58. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for *Clostridium difficile*-associated diarrhea: a cohort study during an epidemic in Quebec. *Clin Infect Dis.* 2005;41:1254–60.
 59. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. *Clostridium difficile*-associated disease in a setting of endemicity: identification of novel risk factors. *Clin Infect Dis.* 2007;45:1543–9.
 60. Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for *Clostridium difficile* infection. *Clin Infect Dis.* 2008;46:19–31.
 61. McCusker ME, Harris AD, Perencevich E, Roghmann M. Fluoroquinolone use and *Clostridium difficile*-associated diarrhea. *Emerg Infect Dis.* 2003;9:730–3.
 62. Gerding DN, Olson MM, Peterson LR, Teasley LR, Gebhard RL, Schwartz ML, et al. *Clostridium difficile*-associated diarrhea and colitis in adults. *Arch Intern Med.* 1986;146:95–100.
 63. Brown E, Talbot GH, Axelrod P, Provencher M, Hoegg C. Risk factors for *Clostridium difficile* toxin-associated diarrhea. *Infect Control Hosp Epidemiol.* 1990;11:283–90.
 64. Iv EC, Iii EC, Johnson DA. Clinical update for the diagnosis and treatment of *Clostridium difficile* infection. *World J Gastrointest Pharmacol Ther.* 2014;5:1–26.
 65. Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolini R, De Lalla F. Prospective study of *Clostridium difficile* intestinal colonization and disease

- following single-dose antibiotic prophylaxis in surgery. *Antimicrob Agents Chemother.* 1991;35:208–10.
66. Yee J, Dixon CM, McLean AP, Meakins JL. Clostridium difficile disease in a department of surgery. The significance of prophylactic antibiotics. *Arch Surg.* 1991;126:241–6.
 67. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. *J Hosp Infect.* 2003;54:243–5.
 68. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. *CMAJ.* 2004;171:33–8.
 69. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. *Am J Gastroenterol.* 2012;107(7):1011–9.
 70. Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. *QJM.* 2000;93:175–81.
 71. Kent KC, Rubin MS, Wroblewski L, Hanff PA, Silen W. The impact of Clostridium difficile on a surgical service: a prospective study of 374 patients. *Ann Surg.* 1998;227:296–301.
 72. McDonald LC, Killgore GE, Thompson A, Owens Jr RC, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. *N Eng Jour Med.* 2005;353:2433–41.
 73. Rodrigues MA, Brady RR, Rodrigues J, Graham C, Gibb AP. Clostridium difficile infection in general surgery patients; identification of high-risk populations. *Int J Surg.* 2010;8:368–72.
 74. Kim MJ, Kim BS, Kwon JW, Ahn SE, Lee SS, Park HC, et al. Risk factors for the development of Clostridium difficile colitis in a surgical ward. *J Korean Surg Soc.* 2012;83:14–20.
 75. Yasunaga H, Horiguchi H, Hashimoto H, Matsuda S, Fushimi K. The burden of Clostridium difficile-associated disease following digestive tract surgery in Japan. *J Hosp Infect.* 2012;82:175–80.
 76. Wren SM, Ahmed N, Jamal A, Safadi BY. Preoperative oral antibiotics in colorectal surgery increase the rate of Clostridium difficile colitis. *Arch Surg.* 2005;140:752–6.
 77. Yeom CH, Cho MM, Baek SK, Bae OS. Risk Factors for the Development of Clostridium difficile-associated Colitis after Colorectal Cancer Surgery. *J Korean Soc Coloproctol.* 2010;26:329–33.
 78. Damle RN, Cherrng NB, Flahive JM, Davids JS, Maykel JA, Sturrock PR, et al. Clostridium difficile infection after colorectal surgery: a rare but costly complication. *J Gastrointest Surg.* 2014;18:1804–11.
 79. Lumpkins K, Bochicchio GV, Joshi M, Gens R, Bochicchio K, Conway A, et al. Clostridium difficile infection in critically injured trauma patients. *Surg Infect.* 2008;9:497–501.
 80. Egorova NN, Siracuse JJ, McKinsey JF, Nowygrod R. Trend, risk factors and costs of Clostridium Difficile infections in vascular surgery. *Ann Vasc Surg.* 2015;50890-5096(15):00015–1.
 81. Navaneethan U, Mukewar S, Venkatesh PG, Lopez R, Shen B, Nitzan O, et al. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. *J Crohns Colitis.* 2012;6:330–6.
 82. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. *Dig Dis Sci.* 2010;55:415–20.
 83. Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, et al. Impact of Clostridium difficile on inflammatory bowel disease. *Clin Gastroenterol Hepatol.* 2007;5:345–51.
 84. Ananthkrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. *Gut.* 2008;57:205–10.
 85. Clayton EM, Rea MC, Shanahan F, Quigley EM, Kiely B, Hill C, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. *Am J Gastroenterol.* 2009;104:1162–9.
 86. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. *Aliment Pharmacol Ther.* 2009;30:253–64.
 87. Kariv R, Navaneethan U, Venkatesh PG, Lopez R, Shen B. Impact of Clostridium difficile infection in patients with ulcerative colitis. *J Crohns Colitis.* 2011;5:34–40.
 88. Absah I, Faubion WA. Concomitant therapy with methotrexate and anti-TNF- α in pediatric patients with refractory crohn's colitis: a case series. *Inflamm Bowel Dis.* 2012;18:1488–92.
 89. Rodemann JF, Dubberke ER, Reske KA, da Seo H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. *Clin Gastroenterol Hepatol.* 2007;5:339–44.
 90. Tsironi E, Irving PM, Feakins RM, Rampton DS. "Diversion" colitis caused by Clostridium difficile infection: report of a case. *Dis Colon Rectum.* 2006;49:1074–7.
 91. Li Y, Qian J, Queener E, Shen B. Risk factors and outcome of PCR-detected Clostridium difficile infection in ileal pouch patients. *Inflamm Bowel Dis.* 2013;19:397–403.
 92. Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. *J Crohns Colitis.* 2010;4:194–8.
 93. Yanai H, Nguyen GC, Yun L, Lebowitz O, Navaneethan U, Stone CD, et al. Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: antibiotics alone or combined antibiotics/immunomodulators? *Inflamm Bowel Dis.* 2011;17:1540–6.
 94. Albright JB, Bonatti H, Mendez J, Kramer D, Stauffer J, Hinder R, et al. Early and late onset Clostridium difficile-associated colitis following liver transplantation. *Transpl Int.* 2007;20(10):856–66.
 95. Chopra T, Alangaden GJ, Chandrasekar P. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. *Expert Rev Anti Infect Ther.* 2010;8(10):1113–9.
 96. Rodríguez Garzotto A, Mérida García A, Muñoz Unceta N, Galera Lopez MM, Orellana-Miguel MA, Díaz-García CV, et al. Risk factors associated with Clostridium difficile infection in adult oncology patients. *Support Care Cancer.* 2014 Nov 20. [Epub ahead of print]
 97. Haines CF, Moore RD, Bartlett JG, Sears CL, Cosgrove SE, Carroll K, et al. Clostridium difficile in a HIV-infected cohort: incidence, risk factors, and clinical outcomes. *AIDS.* 2013;27(17):2799–807.
 98. Collini PJ, Kuijper E, Dockrell DH. Clostridium difficile infection in patients with HIV/AIDS. *Curr HIV/AIDS Rep.* 2013;10(3):273–82.
 99. Zhu Y, Wang L, Feng S, Wang S, Zheng C, Wang J, et al. Risk factors for Clostridium difficile-associated diarrhea among cancer patients. *Zhonghua Zhong Liu Za Zhi.* 2014;36(10):773–7.
 100. Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. *Infect Drug Resist.* 2014;7:63–72.
 101. Khanna S, Pardi DS, Aronson SL, Kammer PP, Baddour LM. Outcomes in community-acquired Clostridium difficile infection. *Aliment Pharmacol Ther.* 2012;35(5):613–8.
 102. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. *J Hosp Infect.* 2008;70:298–304.
 103. Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, Finney J, et al. Infections in Oxfordshire Research Database. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. *Clin Infect Dis.* 2012;55:77–87.
 104. Zilberberg MD, Reske K, Olsen M, Yan Y, Dubberke ER. Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study. *BMC Infect Dis.* 2014;14:306.
 105. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Hernandez AV, et al. Risk Factors for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis. *Infect Control Hosp Epidemiol.* 2015 Jan 28:1–9. [Epub ahead of print]
 106. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. *Clin Infect Dis.* 2012;55:154–61.
 107. McFarland LV, Clarridge JE, Bened HW, Raugi GJ. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. *Clin Infect Dis.* 2007;45:1141–51.
 108. Jaber MR, Olafsson S, Fung WL, Reeves ME. Clinical review of the management of fulminant clostridium difficile infection. *Am J Gastroenterol.* 2008;103(12):3195–203.
 109. Kazanowski M, Smolarek S, Kinnarney F, Grzebieniak Z. Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities - a systematic review. *Tech Coloproctol.* 2014;18:223–32.
 110. Welfare MR, Lalayiannis LC, Martin KE, Corbett S, Marshall B, Sarma JB. Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. *J Hosp Infect.* 2011;79:359–63.

111. Hu MY, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V, et al. Prospective derivation and validation of a clinical prediction rule for recurrent *Clostridium difficile* infection. *Gastroenterology*. 2009;136:1206–14.
112. Voelker R. Increased *Clostridium difficile* virulence demands new treatment approach. *JAMA*. 2010;26:2017–9.
113. Bauer MP, Hensgens MPM, Miller MA, Gerding DN, Wilcox MH, Dale AP, et al. Renal failure and leukocytosis are predictors of a complicated course of *Clostridium difficile* infection if measured on day of diagnosis. *Clin Infect Dis*. 2012;55:149–53.
114. Abou Chakra CN, Pepin J, Valiquette L. Prediction tools for unfavourable outcomes in *Clostridium difficile* infection: a systematic review. *PLoS ONE*. 2012;7:e30258.
115. Miller MA, Louie T, Mullane K, Weiss K, Lentnek A, Golan Y, et al. Derivation and validation of a simple clinical bedside score (ATLAS) for *Clostridium difficile* infection which predicts response to therapy. *BMC Infect Dis*. 2013;13:148.
116. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol*. 2010;31:431–55.
117. Flegel W, Muller F, Daubener W, Fisher HG, Hadding U, Northoff H. Cytokine response by human monocytes to *Clostridium difficile* toxin A and toxin B. *Infect Immun*. 1991;59:3659–66.
118. Castagliuolo I, Keates AC, Wang CC, Pasha A, Valenick L, Kelly CP, et al. *Clostridium difficile* toxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells. *J Immunol*. 1998;160:6039–45.
119. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, et al. Fulminant *Clostridium difficile*: an underappreciated and increasing cause of death and complications. *Ann Surg*. 2002;235:363–72.
120. Adams SD, Mercer DW. Fulminant *Clostridium difficile* colitis. *Curr Opin Crit Care*. 2007;13:450–5.
121. Malnick SD, Zimhony O. Treatment of *Clostridium difficile*-associated diarrhea. *Ann Pharmacother*. 2002;36:1767–75.
122. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent *Clostridium difficile* disease. *Am J Gastroenterol*. 2002;97:1769–75.
123. Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, Finney J, et al. Predictors of first recurrence of *Clostridium difficile* infection: Implications for initial management. *Clin Infect Dis*. 2012;55 Suppl 2:S77–87.
124. Hu MY, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V, et al. Prospective derivation and validation of a clinical prediction rule for recurrent *Clostridium difficile* infection. *Gastroenterology*. 2009;136:1206–14.
125. Kelly JP. Can we identify patients at high risk of recurrent *Clostridium difficile* infection? *Clin Microbiol Infect*. 2012;18 Suppl 6:21–7.
126. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent *Clostridium difficile* diarrhea: Characteristics of and the risk factors for patients enrolled in a prospective, randomized, double-blinded trial. *Clin Infect Dis*. 1997;24(3):324–33.
127. Samie AA, Traub M, Bachmann K, Kopschke K, Theilmann L. Risk factors for recurrence of *Clostridium difficile*-associated diarrhea. *Hepatogastroenterology*. 2013;60(126):1351–4.
128. LaBarbera FD, Nikiforov I, Parvathani A, Pramil V, Gorrepati S. A prediction model for *Clostridium difficile* recurrence. *J Community Hosp Intern Med Perspect*. 2015;5(1):26033.
129. Hookman P, Barkin JS. *Clostridium difficile* associated infection, diarrhea and colitis. *World J Gastroenterol*. 2009;15:1554–80.
130. Tabak YP, Zilberberg MD, Johannes RS, Sun X, McDonald LC. Attributable burden of hospital-onset *Clostridium difficile* infection: a propensity score matching study. *Infect Control Hosp Epidemiol*. 2013;34:588–96.
131. Campbell R, Dean B, Nathanson B, Haidar T, Strauss M, Thomas S. Length of stay and hospital costs among high-risk patients with hospital-origin *Clostridium difficile*-associated diarrhea. *J Med Econ*. 2013;16:440–8.
132. Magalini S, Pepe G, Panunzi S, Spada PL, De Gaetano A, Gui D. An economic evaluation of *Clostridium difficile* infection management in an Italian hospital environment. *Eur Rev Med Pharmacol Sci*. 2012;16(15):2136–41.
133. Skovrlj B, Guzman JZ, Silvestre J, Al Maieeh M, Qureshi SA. *Clostridium difficile* colitis in patients undergoing lumbar spine surgery. *Spine*. 2014;39:1167–73.
134. Mittal C, Hassan S, Arshad S, Jeepalyam S, Bruni S, Miceli M, et al. *Clostridium difficile* infection in liver transplant recipients: a retrospective study of rates, risk factors and outcomes. *Am J Transplant*. 2014;14:1901–7.
135. Lee DY, Chung EL, Guend H, Whelan RL, Wedderburn RV, Rose KM. Predictors of mortality after emergency colectomy for *Clostridium difficile* colitis: an analysis of ACS-NSQIP. *Ann Surg*. 2014;259:148–56.
136. Barbut F, Surgers L, Eckert C, Visseaux B, Cuingnet M, Mesquita C, et al. Does a rapid diagnosis of *Clostridium difficile* infection impact on quality of patient management? *Clin Microbiol Infect*. 2014;20(2):136–44.
137. Kundrapu S, Sunkesula VC, Jury LA, Sethi AK, Donskey CJ. Utility of perirectal swab specimens for diagnosis of *Clostridium difficile* infection. *Clin Infect Dis*. 2012;55(11):1527–30.
138. Carroll KC. Tests for the diagnosis of *Clostridium difficile* infection: the next generation. *Anaerobe*. 2011;17:170–4.
139. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of *Clostridium difficile* and serum levels of IgG antibody against toxin A. *N Engl J Med*. 2000;342:390–7.
140. Planche T, Aghaizu A, Holliman R, Riley P, Poloniecki J, Breathnach A, et al. Diagnosis of *Clostridium difficile* infection by toxin detection kits: a systematic review. *Lancet Infect Dis*. 2008;8:777–84.
141. Brecher SM, Novak-Weekley SM, Nagy E. Laboratory diagnosis of *Clostridium difficile* infections: there is light at the end of the colon. *Clin Infect Dis*. 2013;57:1175–81.
142. Lyerly DM, Barroso LA, Wilkins TD. Identification of the latex test-reactive protein of *Clostridium difficile* as glutamate dehydrogenase. *J Clin Microbiol*. 1991;29:2639–42.
143. Schmidt ML, Gilligan PH. *Clostridium difficile* testing algorithms: what is practical and feasible? *Anaerobe*. 2009;15:270–3.
144. Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, et al. Differences in outcome according to *Clostridium difficile* testing method: a prospective multicentre diagnostic validation study of *C difficile* infection. *Lancet Infect Dis*. 2013;13:936–45.
145. Ros PR, Buetow PC, Pantograg-Brown L, Forsmark CE, Sobin LH. Pseudomembranous colitis. *Radiology*. 1996;198:1–9.
146. Merine DS, Fishman EK, Jones B. Pseudomembranous colitis: CT evaluation. *J Comput Assist Tomogr*. 1987;2:1017–20.
147. Fishman EK, Kavuru M, Jones B, Kuhlman JE, Merine DS, Lillimoe KD, et al. Pseudomembranous colitis: CT evaluation of 26 cases. *Radiology*. 1991;180:57–60.
148. Boland GW, Lee MJ, Cats AM, Gaa JA, Saini S, Mueller PR. Antibiotic-induced diarrhea: specificity of abdominal CT for the diagnosis of *Clostridium difficile* disease. *Radiology*. 1994;191:103–6.
149. Wang MF, Ding Z, Zhao J, Jiang CQ, Liu ZS, Qian Q. Current role of surgery for the treatment of fulminant *Clostridium difficile* colitis. *Chin Med J (Engl)*. 2013;126:949–56.
150. Kirkpatrick ID, Greenberg HM. Evaluating the CT diagnosis of *Clostridium difficile* colitis: should CT guide therapy? *Am J Roentgenol*. 2001;176:635–9.
151. Abu-Zidan FM. Point-of-care ultrasound in critically ill patients: Where do we stand? *J Emerg Trauma Shock*. 2012;5:70–1.
152. O'Malley ME, Wilson SR. US of gastrointestinal tract abnormalities with CT correlation. *Radiographics*. 2003;23:59–72.
153. Downey DB, Wilson SR. Pseudomembranous colitis: sonographic features. *Radiology*. 1991;180:61–4.
154. Ramachandran I, Sinha R, Rodgers P. Pseudomembranous colitis revisited: spectrum of imaging findings. *Clin Radiol*. 2006;61:535–44.
155. Razzag R, Sukumar SA. Ultrasound diagnosis of clinically undetected *Clostridium difficile* toxin colitis. *Clin Radiol*. 2006;61:446–52.
156. Hookman P, Barkin JS. *Clostridium difficile* associated infection, diarrhea and colitis. *World J Gastroenterol*. 2009;15:1554–158.
157. Johal SS, Hammond J, Solomon K, James PD, Mahida YR. *Clostridium difficile* associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. *Gut*. 2004;53:673–7.
158. Kyne L, Merry C, O'Connell B, Kelly A, Keane C, O'Neill D. Factors associated with prolonged symptoms and severe disease due to *Clostridium difficile*. *Age Ageing*. 1999;28:107–13.
159. Bagdasarain N, Rao K, Malani PN. Diagnosis and treatment of *Clostridium difficile* in adults: a systematic review. *JAMA*. 2015;313(4):398–408.
160. Bartlett JG. The case for vancomycin as the preferred drug for treatment of *Clostridium difficile* infection. *Clin Infect Dis*. 2008;46:1489–92.
161. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, et al. Prospective randomised trial of metronidazole vs vancomycin for *Clostridium difficile*-associated diarrhea and colitis. *Lancet*. 1983;2:1043–6.
162. Fekety R, Silva J, Buggy B, Deery HG. Treatment of antibiotic-associated colitis with vancomycin. *J Antimicrob Chemother*. 1984;14:97–102.

163. Bartlett JG, Tedesco FJ, Shull S, Lowe B, Chang T. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. *Gastroenterology*. 1980;78:431–4.
164. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for *Clostridium difficile* infection. *N Engl J Med*. 2011;364:422–31.
165. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus vancomycin for infection with *Clostridium difficile* in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. *Lancet Infect Dis*. 2012;12:281–9.
166. Gerber M, Ackermann G. OPT-80. A macrocyclic antimicrobial agent for the treatment of *clostridium difficile* infections: a review. *Exp Opin Investig Drugs*. 2008;17:547–53.
167. Nelson RL. Antibiotic treatment for *Clostridium difficile*-associated diarrhea in adults. *Cochrane Database Syst Rev*. 2011;7(9):CD004610.
168. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile* -associated diarrhea, stratified by disease severity. *Clin Infect Dis*. 2007;45:302–7.
169. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of *Clostridium difficile* -associated disease with metronidazole and vancomycin. *Clin Infect Dis*. 2008;47:56–62.
170. Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, et al. Vancomycin, metronidazole, or tolevamer for *Clostridium difficile* infection: results from two multinational, randomized, controlled trials. *Clin Infect Dis*. 2014;59(3):345–54.
171. Kim PK, Huh HC, Cohen HW, Feinberg EJ, Ahmad S, Coyle C, et al. Intracolonic vancomycin for severe *Clostridium difficile* colitis. *Surg Infect*. 2013;14:532–9.
172. Eiland 3rd EH, Sawyer AJ, Massie NL. Fidaxomicin Use and Clinical Outcomes for *Clostridium difficile*-Associated Diarrhea. *Infect Dis Clin Pract (Baltim Md)*. 2015;23(1):32–5.
173. Vargo CA, Bauer KA, Mangino JE, Johnston JE, Goff DA. An antimicrobial stewardship program's real-world experience with fidaxomicin for treatment of *Clostridium difficile* infection: a case series. *Pharmacotherapy*. 2014;34(9):901–9.
174. Herpers BL, Vlamincx B, Burkhardt O, Blom H, Biemond-Moeniralam HS, Hornef M, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory *Clostridium difficile* infection. *Clin Infect Dis*. 2009;48:1732–5.
175. El-Herte RL, Baban TA, Kanj SS. Recurrent refractory *Clostridium difficile* colitis treated successfully with rifaximin and tigecycline: A case report and review of the literature. *Scan J Infect Dis*. 2012;44:228–30.
176. Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ. *Clostridium difficile* colitis that fails conventional metronidazole therapy: response to nitazoxanide. *J Antimicrob Chemother*. 2007;59(4):705–10.
177. Girotra M, Kumar V, Khan JM, Damisse P, Abraham RR, Aggarwal V, et al. Clinical predictors of fulminant colitis in patients with *Clostridium difficile* infection. *Saudi J Gastroenterol*. 2012;18:133–9.
178. Khanna S, Pardi DS. *Clostridium difficile* infection: new insights into management. *Mayo Clin Proc*. 2012;87:1106–17.
179. Clanton J, Fawley R, Haller N, Daley T, Porter J, Paranjape C, et al. Patience is a virtue: an argument for delayed surgical intervention in fulminant *Clostridium difficile* colitis. *Am Surg*. 2014;80(6):614–9.
180. Carchman EH, Peitzman AB, Simmons RL, Zuckerbraun BS. The role of acute care surgery in the treatment of severe, complicated *Clostridium difficile*-associated disease. *J Trauma Acute Care Surg*. 2012;73:789–800.
181. Stewart DB, Hollenbeak CS, Wilson MZ. Is colectomy for fulminant *Clostridium difficile* colitis life saving? A systematic review. *Colorectal Dis*. 2013;15:798–804.
182. Ali SO, Welch JP, Dring RJ. Early surgical intervention for fulminant pseudomembranous colitis. *Am Surg*. 2008;74:20–6.
183. Chan S, Kelly M, Helme S, Gossage J, Modarai B, Forshaw M. Outcomes following colectomy for *Clostridium difficile* colitis. *Int J Surg*. 2009;7:78–81.
184. Hall JF, Berger D. Outcome of colectomy for *Clostridium difficile* colitis: a plea for early surgical management. *Am J Surg*. 2008;196:384–8.
185. Osman KA, Ahmed MH, Hamad MA, Mathur D. Emergency colectomy for fulminant *Clostridium difficile* colitis: Striking the right balance. *Scan J Gastroenterol*. 2011;46:1222–7.
186. Seder CW, Villalba Jr MR, Robbins J, Ivascu FA, Carpenter CF, Dietrich M, et al. Early colectomy may be associated with improved survival in fulminant *Clostridium difficile* colitis: An 8-year experience. *Am J of Surg*. 2009;197:302–7.
187. van der Wilden GM, Chang Y, Cropano C, Subramanian M, Schipper IB, Yeh DD, et al. Fulminant *Clostridium difficile* colitis: prospective development of a risk scoring system. *J Trauma Acute Care Surg*. 2014;76:424–30.
188. Ferrada P, Velopulos CG, Sultan S, Haut ER, Johnson E, Praba-Egge A, et al. Timing and type of surgical treatment of *Clostridium difficile*-associated disease: a practice management guideline from the Eastern Association for the Surgery of Trauma. *J Trauma Acute Care Surg*. 2014;76:1484–93.
189. Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, et al. Fulminant *Clostridium difficile* colitis: patterns of care and predictors of mortality. *Arch Surg*. 2009;144:433–9.
190. Lee DY, Chung EL, Guend H, Whelan RL, Wedderburn RV, Rose KM. Predictors of mortality after emergency colectomy for *Clostridium difficile* colitis: an analysis of ACS-NSQIP. *Ann Surg*. 2014;259:148–56.
191. Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P, West Midlands Research Collaborative. Systematic review and meta-analysis of outcomes following emergency surgery for *Clostridium difficile* colitis. *Br J Surg*. 2012;99:1501–13.
192. Lamontagne F, Labbé AC, Haecq O, Lesur O, Lalancette M, Patino C, et al. Impact of emergency colectomy on survival of patients with fulminant *Clostridium difficile* colitis during an epidemic caused by a hypervirulent strain. *Ann Surg*. 2007;245:267–72.
193. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated *Clostridium difficile* associated disease. *Ann Surg*. 2011;254:423–37.
194. Olivas AD, Umanskiy K, Zuckerbraun B, Alverdy JC. Avoiding colectomy during surgical management of fulminant *Clostridium difficile* colitis. *Surg Infect*. 2010;11:299–305.
195. Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, Finney J, et al. Infections in Oxfordshire Research Database. Predictors of first recurrence of *Clostridium difficile* infection: implications for initial management. *Clin Infect Dis*. 2012;55:77–87.
196. O'Horo JC, Jindai K, Kunzer B, Safdar N. Treatment of recurrent *Clostridium difficile* infection: a systematic review. *Infection*. 2014;42:43–59.
197. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of *Clostridium difficile* infection: fidaxomicin versus vancomycin. *Clin Infect Dis*. 2012;55:154–61.
198. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent *Clostridium difficile* disease. *Am J Gastroenterol*. 2002;97(7):1769–75.
199. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standard antibiotics for *Clostridium difficile* disease. *JAMA*. 1994;271:1913–8.
200. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, et al. The search for a better treatment for recurrent *Clostridium difficile* disease: use of high-dose vancomycin combined with *Saccharomyces boulardii*. *Clin Infect Dis*. 2000;31:1012–7.
201. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of *Clostridium difficile* disease. *Am J Gastroenterol*. 2006;101:812–22.
202. Johnson S, Maziade PJ, McFarland LV, Trick W, Donskey C, Currie B, et al. Is primary prevention of *Clostridium difficile* infection possible with specific probiotics? *Int J Infect Dis*. 2012;16(11):e786–92.
203. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Treating *Clostridium difficile* infection with fecal microbiota transplantation. *Clin Gastroenterol Hepatol*. 2011;9:1044–9.
204. Khanna S, Pardi DS. *Clostridium difficile* infection: new insights into management. *Mayo Clin Proc*. 2012;87:1106–17.
205. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent *Clostridium difficile* infection. *Clin Infect Dis*. 2011;53:994–1002.
206. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of *Clostridium difficile* infection: a systematic review. *J Clin Gastroenterol*. 2014;48(8):693–702.
207. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for *Clostridium difficile* infection: systematic review and meta-analysis. *Am J Gastroenterol*. 2013;108(4):500–8.
208. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med*. 2013;368:407–15.

209. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing *Clostridium difficile* infection. *JAMA*. 2014;312(17):1772–8.
210. Di Bella S, Gouliouris T, Petrosillo N. Fecal microbiota transplantation (FMT) for *Clostridium difficile* infection: Focus on immunocompromised patients. *J Infect Chemother*. 2015;21(4):230–7.
211. Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. Fecal microbiota transplant for treatment of *Clostridium difficile* infection in immunocompromised patients. *Am J Gastroenterol*. 2014;109:1065–71.
212. Abourgergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of *Clostridium difficile* infection: a review. *Dig Dis Sci*. 2011;56:19–26.
213. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, et al. Treatment with monoclonal antibodies against *Clostridium difficile* toxins. *N Engl J Med*. 2010;362:197–205.
214. Sullivan PB. Nutritional management of acute diarrhea. *Nutrition*. 1998;14:758–62.
215. Choi EY, Park DA, Park J. Calorie Intake of Enteral Nutrition and Clinical Outcomes in Acutely Critically Ill Patients: A Meta-Analysis of Randomized Controlled Trials. *JPEN J Parenter Enteral Nutr*. 2014 Jul 30. [Epub ahead of print]
216. Gerding DN. Acquisition of *Clostridium difficile* and *Clostridium difficile*-associated diarrhea in hospitalized patients receiving tube feeding. *Ann Intern Med*. 1998;129:1012–9.
217. Bliss DZ, Johnson S, Savik K, Clabots CL, Willard K, Gerding DN. Acquisition of *C. difficile* and *C. diff*-associated diarrhea in hospitalized patients receiving tube feeding. *Ann Intern Med*. 1998;129:1012–9.
218. O'Keefe SJ. A guide to enteral access procedures and enteral nutrition. *Nat Rev Gastroenterol Hepatol*. 2009;6:207–15.
219. O'Keefe SJ. Tube feeding, the microbiota, and *Clostridium difficile* infection. *World J Gastroenterol*. 2010;16(2):139–42.
220. Puri BK, Hakkarainen-Smith J, Monro JA. The potential use of cholestyramine to reduce the risk of developing *Clostridium difficile*-associated diarrhoea in patients receiving long-term intravenous ceftriaxone. *Med Hypotheses*. 2015;84:78–80.
221. Westh H, Iversen JT, Gyrttrup HJ. *Clostridium difficile* in faecal flora after perioperative prophylaxis with ampicillin or ceftriaxone. *J Infect*. 1991;23:347–50.
222. Olson A, Diebel LN, Liberati DM. Effect of host defenses on *Clostridium difficile* toxin-induced intestinal carrier injury. *J Trauma Acute Care Surg*. 2013;74:983–90.
223. Diebel LN, Liberati DM. Reinforcement of the intestinal mucus layer protects against *Clostridium difficile* intestinal injury in vitro. *J Am Coll Surg*. 2014;219:460–9.
224. Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility agents for the treatment of *Clostridium difficile* diarrhea and colitis. *Clin Infect Dis*. 2009;48(5):598–605.
225. Piacenti FJ, Leuthner KD. Antimicrobial stewardship and *Clostridium difficile*-associated diarrhea. *J Pharm Pract*. 2013;26:506–13.
226. Feazel LM, Malhotra A, Perencevich EN, Kaboli P, Diekema DJ, Schweizer ML. Effect of antibiotic stewardship programmes on *Clostridium difficile* incidence: a systematic review and meta-analysis. *J Antimicrob Chemother*. 2014;69:1748–54.
227. Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev*. 2013;4, CD003543.
228. Marufu O, Desai N, Aldred D, Brown T, Eltringham I. Analysis of interventions to reduce the incidence of *Clostridium difficile* infection at a London teaching hospital trust, 2003–2011. *J Hosp Infect*. 2014;89(1):38–45.
229. Owens RC. *Clostridium difficile*-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy*. 2006;26:299–311.
230. Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. *Infect Control Hosp Epidemiol*. 1996;17:53–80.
231. Vonberg RP, Kuijper EJ, Wilcox MH, Barbut F, Tull P, Gastmeier P, et al. Infection control measures to limit the spread of *Clostridium difficile*. *Clin Microbiol Infect*. 2008;14:2–20.
232. Chang VT, Nelson K. The role of physical proximity in nosocomial diarrhea. *Clin Infect Dis*. 2000;31:717–22.
233. Willt M, Odenhott I, Walder M. Activity of three disinfectants and acidified nitrate against *Clostridium difficile* spores. *Infect Control Hosp Epidemiol*. 2003;24:765–8.
234. Landelle C, Verachten M, Legrand P, Girou E, Barbut F, Brun-Buisson C. Contamination of healthcare workers' hands with *Clostridium difficile* spores after caring for patients with *C. difficile* infection. *Infect Control Hosp Epidemiol*. 2014;35(1):10–5. doi:10.1086/674396. Epub 2013 Nov 26.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

